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ABSTRACT
The 3 amyloid protein is the primary constituent 
of amyloid plaques in the brains of Alzheimer's disease 
patients. The generation of 3 amyloid protein from 3 
amyloid precursor protein and its interaction with 
neuronal cells were studied in the mouse neuroblastoma 
cell line NB41A3. Immunoreactivity to the carboxyl 
terminal of the precursor protein was detected among 
the membrane proteins of these cells, indicating that 3 
amyloid precursor protein is produced by NB41A3 cells. 
Also amyloid precursor protein carboxyl terminal 
immunoreactivity was observed in the conditioned medium 
of the cells, demonstrating various cytosolic peptide 
fragments are secreted during the cellular processing 
of the 3 amyloid precursor protein. Synthetic 3 amyloid 
peptide was shown to negatively affect NB41A3 
neuroblastoma cells as judged by decreasing cell 
numbers, decreasing amount of cell protein, and release 
of the cytosolic enzyme, lactic dehydrogenase, into the 
medium. At the ultrastructural level, internal damage 
to the nucleus could be observed. Synthetic 3 pepide 
showed specific binding with neuroblastoma cells. The 
internalization of the 3 peptide into the cells suggest 
a direct mechanism for 3 amyloid protein toxicity in 
vivo. This research contributes to the knowledge of the 
processing of Alzheimer's disease 3 amyloid precursor 
protein in NB41A3 cells and demonstrates that NB41A3 
cell provides a practical in vitro model for studying 
the mechanism of Alzheimer's disease and amyloid 
toxicity.
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1Chapter 1. 
Introduction
Alzheimer's disease (AD) is the most common form 
of cerebral degeneration leading to dementia in elderly 
people. It is a late onset neurodegenerative disorder 
disease causing widespread functional disturbance of 
the human brain. The typical clinical presentation of 
AD is quite characteristic, with deficits in short term 
memory present early in the course of the disease. 
Eventually, the dementia spreads to affect language 
skills, abstract thinking, judgment, and visual-spatial 
orientation.
Alzheimer's disease occurs in two to four million 
individuals in the United States. It is estimated that 
AD afflicts 5 to 11 percent of the population over the 
age of 65 and as much as 47 percent of the population 
over the age of 85 (Yankner & Mesulam, 1991) . The 
obvious impact of this fact on health care has 
stimulated interest in research aimed at understanding 
the etiology and pathogenesis of this disease.
Alzheimer's disease was first reported by 
Alzheimer in 1907. The abnormal amyloid deposits or 
amyloid plaques in certain areas of the brain of a
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
diseased patient have become the histopathological 
characteristic of Alzheimer's disease. Definitive 
diagnosis of Alzheimer's disease requires the 
confirmation of insoluble proteinaceous deposits in the 
brain by either autopsy or biopsy. There are two 
general types of deposits: 1) extracellular amyloid
deposits in senile plaques and in cerebral blood
vessels; and 2) intracellular neurofibrillary tangles 
in the cytoplasm of neurons (Terry & Katzman 1983 ; 
Glenner & Wong 1984). The reduction in the number of 
neurons and synapses, as well as the gradual
accumulation of amyloid plaques and neurofibrillary 
tangles, occur predominantly in the frontal, temporal 
and parietal lobes, and in the amygdala and thalamus 
(Masliah et al. , 1989; Masliah et al. , 1991; Terry et
al., 1983; Hamos et al., 1989). The observation that a
reduction in the number of neurons accompanies a 
gradual accumulation of amyloid plaques in AD brains 
suggests a correlation between the degree of dementia 
and the number of plaques.
The extracellular amyloid plaque is composed of an 
amyloid core surrounded by dysfunctional neurites.
Though many proteins are associated with these
extracellular amyloid deposits, the primary constituent
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
of the plaque core that accounts for its fibrillar 
properties is a 4 kilodalton (Kd) protein, called ft 
amyloid protein (ftAP) or ft protein. Using a synthetic 
fragment of ft amyloid protein, ftl-40, and a cultured 
mouse neuroblastoma cell line NB41A3 as an experimental 
model, this research project investigates the 
interaction between individual cells and the ft amyloid 
protein. Will ftl-40 have a biological effect on 
cultured neuroblastoma cells? Does amyloid ft peptide 
interact with cells by binding to the cell surface? Or 
could amyloid ft peptide be internalized by cells?
This research will be described in six chapters. 
Chapter 2 will review the current research on ft amyloid 
protein and its role in neurodegeneration hypothesis in 
Alzheimer's disease. Chapters 3 - 5  each address a 
different aspect of this research project. Chapter 3 
describes the process of the ft peptide synthesis and 
its purification. Chapter 4 shows the anti - ft amyloid 
precursor protein (ftAPP) immunoreactivities in cultured 
neuroblastoma cells, using antibodies raised against 
synthesized peptides. Chapter 5 reports on 
investigations involving the neurotoxic effects of ftl- 
40 and the mechanism of ft peptide - neuroblastoma 
interaction. Chapter 6 introduces the initial
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
experimental data of an ultrastructural study on 
cultured neuroblastoma cells. Chapter 7 summarizes the 
findings in this research project.
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B Amyloid Protein, B Amyloid Precursor Protein, and 
Alzheimer's Disease: a Review
The characteristic lesions in the brains of AD 
patients are intracellular as well as extracellular 
insoluble proteinaceous fibers called amyloid. 
Intracellular amyloid deposits are named 
neurofibrillary tangles, which consist of paired 10 nm 
filaments as seen under the electron microscope. The 
principle protein subunit in neuorofibrillary tangles 
is the microtubule-associated protein tau. On the other 
hand, extracellular amyloid deposits are called amyloid 
plaques or senile plaques, which contain amyloid cores 
surrounded by dysfunctional neurites. The major protein 
component of the amyloid core is identified as 6 
amyloid protein (BAP).
2-1. Identification of R amyloid protein and B amyloid 
precursor protein
The major proteinaceous component of extracellular 
amyloid deposit in the AD brain was first identified in 
1984. From cerebrovascular amyloid of an AD brain, 
Glenner and Wong (1984) isolated a 4200-dalton protein
Chapter 2
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which, studies indicated, was a major component of 
amyloid plaque. Monoclonal antibodies against this 
protein label both cerebrovascular and extracellular 
plaque amyloid, leaving little doubt that this protein 
is an intrinsic fibril component of amyloid deposits. 
This protein has been named B amyloid protein or B 
protein ( B A P ) .  Amino acid sequencing data indicate that 
BAP is a short peptide containing 42 to 43 amino acid 
residues. It is highly insoluble under physiological 
conditions, which accounts for amyloid deposits' 
fibrillar properties (Masters et al . , 1.985a; 1985b).
Knowledge of the amino acid sequence of BAP has 
provided a means to isolate a full-length cDNA clone 
encoding a large B amyloid protein precursor (BAPP). 
Further sequencing studies indicate that this cDNA 
encodes a protein of 695 amino acid residues; 
therefore, it is referred as B A P P 6g 5 . Near the carboxyl 
terminus of B A P P  is the B amyloid protein region (Kang 
et a l., 1987).
2-2. BAPP domain structure and BAPP function
Soon after the BAPP-encoding cDNA was isolated, 
Kang and colleagues proposed a domain structure of this 
protein based on its deduced amino acid sequence (Kang
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
et al., 1987). Assuming that translation starts at the
first AUG of the cDNA clone, this BAPP would contain 
695 amino acid residues. As shown in Figure 2-1, the 
BAPP695 begins with a signal seguence of 17 amino acid 
residues for transporting the protein through the 
endoplasmic reticulum membrane (Dyrks et al. , 1988).
Following the signal sequence is a cysteine-rich
region, which might help stabilize the protein by 
forming disulfide bonds. The next hundred residues are
extremely rich in negatively charged amino acids; this
region contains 28 glutamic acids and 17 aspartic 
acids, but only one lysine and two arginines. The 
region from residue 290 to residue 597, the N-terminus 
of BAP, contains two potential N-glycosylation sites. 
The amyloid B protein sequence starts at residue 597 of 
the precursor, and terminates at residue 639, 
containing 42 to 43 amino acid residues. The first 28 
amino acids at the N-terminus of BAP are located in the 
extracellular domain of the precursor, while the last 
15 residues are embedded within the cell membrane. The 
C-terminal cleavage of mature precursor during 
amyloidogenesis would have to occur within the 
membrane. The hydrophobic membrane spanning region
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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starts at residue 624 and ends at residue 648, spanning 
the membrane once. The three lysines after the membrane 
spanning region are characteristic features of the 
junction between membrane and cytoplasmic domains of 
cell-surface receptors, and interact with the 
phospholipid head groups in the membrane. The 
cytoplasmic domain of BAPP contains the last 47 amino 
acid residues.
Amyloid B protein precursor is found in both 
cultured cells as well as in a variety of tissues. 
Currently, the normal physiological function of BAPP is 
still unknown. There are reports that suggest BAPP is 
involved in the regulation of cell growth and in the 
regulation of cell - cell or cell - surface adhesion 
(Saitoh et al., 1989; Breen et al., 1991; Brenda et
a l., 1988). Recently, Nishimoto et al. (1993) reported
that BAPP forms a complex with G0, a major ATP binding 
protein in neuronal membranes. A cytoplasmic BAPP 
sequence, histidine 657 - lysine 676 in BAPP695, has
been shown to have a specific G0-activating function, 
and the immunoreactive a- and B- subunits of G0 from 
solubilized brain membranes were co-precipitated with 
BAPP by an anti-BAPP monoclonal antibody. This suggests 
that BAPP may be a receptor protein coupled to G0•
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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2-3. BAPP mRNA isoforms expressed in various tissues
Almost at the same time as BAPP695 was isolated, 
several other research groups independently identified 
two BAPP mRNAs encoding proteins of 770 or 7 51 amino 
acid residues, respectively. The BAPP mRNA identified 
by Tanzi et al., (1988) and Ponteet al. , ( 1988)
contained a sequence identical to that of the 
previously reported BAPP695, except for a 168 base pair 
insertion within the codon for valine 289 of BAPP. The 
insertion preserved the reading frame of the BAPP 
message, contained no termination codon, and would 
introduce 56 amino acids C-terminal to arginine 288 of 
the BAPP. It would also convert valine 289 to an 
isoleucine. A group of polypeptides with sequences 
similar to that of the BAPP insert are members of a 
family of Kunitz-type serine protease inhibitors. This 
insert-containing mRNA encoded 751 amino acid residues. 
Thus it was referred to as BAPP751. In the same year, 
Kitaguchi et al. (1988) isolated the third BAPP mRNA, 
encoding a BAPP770, which contained a 225 base pair 
nucleotide insert introducing 75 additional amino acid 
residues. The 56 amino acid at the N-terminal of the 75 
residue insert was highly homologous to the Kunitz
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
protease inhibitor. The insert of BAPP770 occurred in 
the same position as it did in 6APP751, with valine 289 
replaced by glutamic acid.
The isolation of BAPP-encoding cDNA clones 
reveals that this protein is derived from a much larger 
precursor protein. The precursor protein is synthesized 
in three major forms containing 695, 751, and 770 amino 
acid residues, respectively. All three forms have an 
identical amino acid sequence, except that the two 
longer forms contain a conserved sequence found in the 
family of Kunitz protease inhibitors. It was 
subsequently shown that these isoforms of BAPP mRNA are 
transcripts of alternative splicing of one BAPP gene, 
which was localized to the long arm of chromosome 21 in 
humans. (Goldgaber et al. , 1987; Zabel et al., 1987;
Patterson et al., 1988; Kang et al., 1987).
Kitaguchi et al. (1988) has reported that the
BAPP Kunitz protease inhibitor domain has protease 
inhibitor activity in vitro. In their experiments, COS- 
1 cells were transfected either with an insert- 
containing BAPP695 or with an insert-lacking BAPP770. An 
increase in trypsin activity inhibition was observed in 
B A P P 77q transfected cell lysates.
11
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The mRNAs of BAPP, which result from alternative 
splicing, have been detected in a variety of tissues 
including muscle, spleen, kidney, and epithelial cells. 
Thus, the amyloid precursor protein gene is expressed 
in the brain as well as in other peripheral tissues. 
Ponte et al. (1988) investigated the expression of
BAPP695 and the insert-containing BAPP751 in various
tissues, and found that BAPP751 mRNA appeared to be 
ubiquitous, whereas APP695 mRNA had a restricted 
pattern of expression. When searching cDNA libraries 
prepared from a human SV40 transformed fibroblast cell 
line, lymphocytes, and normal or AD brain, the insert- 
positive clones were identified in all libraries, and 
only the brain libraries contained BAPP695. This 
suggests that the BAPP transcripts might be 
differentially regulated and the insert-lacking BAPP695 
could be specifically expressed in the brain.
Meanwhile, other reports indicated BAPP751 and BAPP770 
levels were significantly increased in AD brain, 
suggesting the possible role of insert-containing BAPP 
in AD (Tanaka et al . , 1988; Johnson et al. , 1990).
Though the subject is still controversial, the fact
that the relative proportion of these alternative forms 
of the BAPP message varies from tissue to tissue has
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
been confirmed. The balance among BAPP isoforms might 
be one of the factors in AD development.
2-4. Familial Alzheimer's disease and mutation of the 
BAPP gene
Although in most cases Alzheimer's disease is a 
late-onset neurodegenerative disease, some people do 
develop AD in their early 50's or even in their late 
40 's. The fact that early-onset AD shows familial 
inheritance suggests that the disease has some genetic 
components. The BAPP has been a suspect gene because:
1) BAP is a major component of amyloid deposits in the 
AD brain; 2) Down's syndrome, which also shows the 
amyloid deposits in the brain similar to AD, has an 
extra copy of chromosome 21, and the BAPP gene is also 
located on the human chromosome 21.
In 1987, St. George-Hyslop et al. (1987) first
showed that Alzheimer's disease was linked to two small 
marker sections of DNA in a band of chromosome 21, 
called q21; one of these two sections has in turn been 
linked with the BAPP gene. However, very soon, other 
research groups (Tanzi et al. , 1987; Schellenberg et
al . , 1988) reported that they did not find an
association between the chromosome 21 site and
13
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Alzheimer's disease in the families they were studying; 
making the case much more complicated.
In 1991, John Hardy's group directly detected
mutations in the BAPP gene from patients in some AD
families (Goate et al. , 1991). The point mutation
involved conversion of valine 717 on BAPP770 to
isoleucine. In other AD families, the valine 717 was 
also reported to be replaced by glycine (Chartier- 
Harlin et al, 1991) or phenylalanine (Murrell et al. , 
1991) . These mutations occur within the transmembrane 
domain two residues from the carboxyl terminus of the B 
protein. Computer analysis predicts that these 
substitutions would make the transmembrane domain more 
hydrophobic and could influence the stability of the 
deposited peptide. Up to now, about a dozen mutations 
in the BAPP gene have been reported in familial 
inherited Alzheimer's disease. From all these studies, 
Hardy concludes that the aberrations in the B amyloid 
precursor protein are sufficient, if not necessary, for 
the development of Alzheimer's disease. However, it is 
clear that mutations in the BAPP gene are relatively 
rare and the defect in the BAPP gene probably accounts 
for, at most, only 20% of the cases of Alzheimer's 
disease.
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Later, Schellenberg et al., (1992) showed that
chromosome 14 was also linked to an inherited form of 
AD that develops unusually early, at about 45 years of 
age. As yet the gene responsible for AD on chromosome 
14 has not been identified, but it is suspected to be 
connected with BAPP synthesis and processing.
Meanwhile, previous evidence of the involvement 
of chromosome 19 in late onset AD (Pericak-Vance et 
al., 1991) has been recently confirmed by the finding
of an association between AD and the apolipoprotein E 
(apoE) locus on chromosome 19 (Corder et al. , 1993;
Schmechel et al . , 1993). ApoE is important in lipid
metabolism and to nerve regeneration. It is also 
reported that apoE has high affinity binding to BAP 
(Strittmatter et al., 1993). Therefore, Alzheimer's
disease is genetically heterogeneous and more than one 
gene is involved.
As of now, the major amino acid residues reported 
to be involved in the BAPP mutations include ( Goate et 
al. , 1991; Chartier-Harlin et al., 1991; Murrell et
al., 1991) :
(1) Lysine 670 of BAPP770 mutates to 
asparagine.
(2) Methionine 671 mutates to leucine.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(3) Glutamate 693 mutates to glutamine.
(4) Valine 717 mutates to isoleucine.
(5) Valine 717 mutates to phenylalanine.
(6) Valine 717 mutates to glycine.
As shown in Figure 2-2, all these mutations are 
located either within or immediately flanking the BAP 
region of BAPP. The lysine 670 and methionine 671 
mutations are right at the amino end of BAP. The 
glutamate 693 mutation is within the BAP sequence, 
while the valine 717 mutation is within the 
transmembrane domain of BAPP, and is only two residues 
away from the C-terminus of BAP. The locations of these 
mutations suggest that they may cause AD by altering 
BAPP processing.
To further investigate the consequences of the
mutations within the BAPP gene, the mutated BAPP genes
have been introduced to various cell culture systems. 
Martin Citron et al. (1992) introduced into the human
kidney 293 cell a BAPP cDNA bearing a double mutation, 
lysine 670 in BAPP770 to asparagine plus methionine 671 
to leucine. They detected six to eight times more BAP
in these cells than in cells transfected with DNA
constructs expressing wild type BAPP. They suggest that 
a methionine to leucine mutation was principally
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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671 extracellular domain transmembrane domain
NHj-r'/VKM- DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIflT -V IV I—/^ C O O H
670 693 717
Figure 2 - 2 . Demonstration of fiAPP mutations found in familial Alzheimer's disease. Open box indicates 
6 AP legion. Lysine-670, methionine-671, glutamate-693, and valine-717 ate amino acids involved in the 
fiAPP mutations in familial Alzheimer's disease. These positions ate either within or immediately flanking 
the fiAP tegion.
responsible for the BAP increase. The fact that 
familial AD mutations increase BAP production was 
further confirmed when Cai et a l . (1993) published a
similar observation in human neuroblastoma cells. Cells 
carrying a mutated BAPP gene produced five times more 
BAP-bearing, carboxyl terminal BAPP derivatives than 
cells expressing wild type BAPP. Besides, they also 
released six times more BAP into the cell culture 
medium. These findings suggested a correlation between 
the amount of released B-amyloid protein and the 
mutations within a BAPP gene.
2-5. Animal models of Alzheimer's disease
Most of the early biochemical evidence linking 
Bamyloid deposits to AD had come from studies on human 
brains obtained at autopsies. The big disadvantage of 
this approach is that the pathological lesions are the 
end stage of the disease. Only rarely do scientists get 
to see what early or intermediate-stage lesions look 
like. While aged nonhuman primates also develop amyloid 
plaques and the other characteristic symptoms of AD, 
including memory deficits, similar to those of 
Alzheimer's disease, the plaques are less frequent and
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the animals are too expensive to be used for routine 
research.
One investigative approach for overcoming this 
difficulty was to develop an animal model of human AD. 
By inducing mice to overproduce B amyloid protein, 
researchers attempted to reproduce neuropathologies and 
behavioral symptoms similar to those of the human 
Alzheimer's disease. If this strategy is successful, it 
would not only confirm the role of BAPP in disease 
pathogenesis, but would also provide an animal model 
which permits researchers to test highly experimental 
drugs against AD and to perform other studies not 
appropriate or possible on humans.
By December 1991, three such transgenic mouse 
models had been reported, of which two showed apparent 
BAP deposits, and a third developed neurofibrillary 
tangles and neurodegeneration (Quon et al., 1991;
Kawabata et al. , 1991; Wirak et al. , 1991). All these
groups used similar genetic engineering approaches. 
They injected genes encoding human B amyloid protein 
precursor into newly fertilized mouse eggs, which were 
then implanted in foster mothers to develop. However 
they chose different isoforms of the BAPP gene.
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In July, 1991, Cordell and her group (Quon et 
al . , 1991) first reported the extracellular amyloid
deposits in their transgenic mice expressing additional 
BAPP751. These amyloid deposits were primarily in the 
cortex and in the hippocampus, two of the principal 
brain areas affected by Alzheimer's disease. However, 
the amyloid deposits in their mice did not have the 
same morphology as observed in humans AD.
At about the same time, Wirak et al. (1991)
reported BAP deposits in the central nervous system of 
their transgenic mice. The Wirak-Underbeck mice model 
also showed BAP immunoreactive deposits in brain 
neurons, particularly in the hippocampus. However, the 
deposits were later found to occur occasionally in 
normal mice of that strain. Later work showed that the 
deposits were also stained nonspecifically by several 
different antibody preparations. This indicated that 
the deposits had a high non-specific affinity for 
antibodies and might not contain B amyloid protein.
In December, another transgenic mouse model was 
reported by Kawabata et al. (1991). The Kawabata-
Higgins-Gordon model reported all the major 
pathological features of AD in the transgenic animals, 
and showed the full range of AD's pathology, including
20
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well-developed plaques, tangles, and degenerating 
neurons. However, the failure to reproduce the results 
in other transgenic mice in later studies made them 
finally retract their paper in March, 1992.
In July, 1992, Kammesheidt et al. (1992) reported 
another transgenic mouse model for human AD. They 
expressed the C-terminal 100 amino acids peptide of 
BAPP in transgenic mice. Using an anti-BAPP-antibody, 
the accumulation of BAPP immunoreactivity in the brains 
of 4- and 6-month-old transgenic mice were studied. 
Only light cytoplasmic staining with antibody was 
visible in control mice, while darker punctuate 
accumulations of immunoreactive stain throughout the 
hippocampus were unique to the transgenic mice. In 
addition, the immunocytochemical analysis using an 
antibody against the carboxyl terminus of BAPP revealed 
aggregation of this epitope of BAPP in neurites with 
abnormal appearing in the area of the hippocampus of 
transgenic mice, similar to its aggregation in the 
cells of AD brains. They suggested the expression of 
abnormal carboxyl terminal subfragments of BAPP in vivo 
may cause amyloidogenesis and specific neuropathology.
21
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
2-6. BAPP processing and BAP release
The amyloid B precursor protein is a glycosylated 
membrane protein with a B amyloid protein sequence 
partially embedded in the membrane. Studies on cultured 
cells documented that BAPP has a short intracellular 
half-life of 20 to 30 minutes with a molecular weight 
ranging from 90 to 135 Kd, depending on the extent of 
glycosylation. During the proteolytic processing, 
breakdown fragments of BAPP appeared both 
intracellularly and extracellularly. The carboxyl- 
terminal truncated BAPP fragments were found to be 
secreted into the cell culture medium. Dewji et al . 
(1990) reported that the intracellular form of BAPP 
appears to undergo amino-terminal processing, yielding 
many smaller fragments, whereas the secreted form does 
not show any further proteolytic cleavage after its 
release from the cell surface.
In addition to the finding of the BAP-region- 
lacking BAPP in cell culture medium, the similar BAPP 
forms lacking BAP region were also detected in the 
human cerebrospinal fluid (Weidemann et a l . , 1989;
Palmert et al., 1989). This evidence indicated that in
normal BAPP processing, the cleavage of BAPP is a 
membrane-associated event that occurs within the BAP
22
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sequence, thus preventing amyloid formation in the 
brain (Sisodia et al . , 1990). Sisdoia et al. (1990)
also showed that the cleavage site on BAPP was close to 
the interface between the extracellular and 
transmembrane domains within the BAP region. Thus, an 
intact amyloidogenic BAP fragment was not generated 
during normal BAPP catabolism. The detection of the 
same BAPP form in human cerebrospinal fluid showed that 
similar events occurred in vivo (Palmert et al. , 1989). 
Therefore, an altered BAPP processing may occur in the 
release and subsequent deposit of the intact BAP 
region.
In a cell culture study, the protein kinase C 
stimulator, phorbol 12,13-dibutyrate, was reported to 
increase the turn-over and processing of BAPP as 
measured by a high level of BAPP degradation fragments 
(Buxbaum et al. , 1990). Protein kinase C activators
were also shown to inhibit BAP production by altering 
its precursor's processing (Gabuzda et a l ., 1993).
Alternatively, because the BAP sequence is partially 
embedded within the membrane, the production of BAP 
could require membrane damage that exposes the embedded 
BAP sequence to a protease, and results in the release 
of BAP by abnormal cleavage of precursor protein within
23
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the cell membrane. The B protein then presumably 
accumulates in the brain because of its low solubility 
under physiological conditions. Thus Pettegrew 
hypothesized that the aberrations in the synthesis and 
degradation of membrane phospholipids were early events 
in the pathogenesis of AD (Pettegrew et al. , 1988a;
1988b). Phospholipid abnormalities in AD brain have 
been reported by several other research groups (Nitsch
et al . , 1992 ; Blusztajn et al . , 1990; Barany et al. ,
1985) since then.
2-7. Neurotoxicity of B amyloid protein
Several in vivo studies have reported brain
damage after the injection of BAP into animals. 
Frautschy et al. (1991) injected SDS isolated AD
amyloid cores into rat hippocampus. The similarly 
isolated lipofuscin fractions from human brains were 
injected on the contralateral side of the brain as 
control. One month after injection, the AD-related 
antigen Alz-50, ubiquitin, and silver positive 
structures were observed only in response to amyloid, 
suggesting that the injection of B amyloid caused 
neuronal damages and induced AD-associated antigens in 
the animals' brains. In a similar experiment using a
24
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synthetic BAP fragment, the neurodegeneration and Alz- 
50 antigen induction were also observed in rat and in 
primate cortices (Kowall et al. , 1991; 1992),
indicating neuronal responses to BAP.
However, several other studies reported that B 
protein failed to produce neurotoxicity after injection 
into rat and monkey brains (Podlisny et al. , 1992;
Games et al . , 1992). While conflicting observations
have been reported regarding the direct in vivo and in
vitro neurotoxicity of BAP, May et al. (1992) pointed
out there were marked lot-to-lot differences in the 
neurotoxic properties of BAP in primary rat hippocampal 
cultures. Attempting to find an explanation, the B 
amyloid peptide preparations with differential 
neurotoxicity were studied extensively. Amino acid
sequencing, HPLC, and mass spectroscopy provided 
evidences that these peptides were all synthesized 
correctly and were free of contamination. Rather, the 
important difference appeared to be related to peptide 
confirmation or aggregation state (Yankner 1992). Pike 
et al. (1991; 1993) has reported that the prolonged
incubation of synthetic B peptide in solution resulted 
in increases of peptide aggregation and neurotoxicity, 
while newly solubilized B amyloid peptide was
2 5
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predominantly monomeric and was not as toxic to 
neurons.
The neurotoxicity of BAP was also reported in 
many in vitro studies on primary neuronal cultures (Loo 
et al., 1993 ; Forloni et al., 1993; Pike et al . , 1992;
Busciglio et al., 1993). Yankner et al. (1990a; 1990b)
showed that BAP could either be trophic or toxic to 
neuronal cells, depending on the stage of the neuronal 
cells and the concentrations of BAP. Based on the 
observations of a primary culture from the rat brain at 
embryonic day 18, they showed that B amyloid protein is 
neurotoxic to mature neurons and also neurotrophic to 
undifferentiated neurons. The BAP toxicity was also 
reported to be dose-dependent and reversible at low 
doses (Roher et al. , 1991). These facts suggest that
the deposit of amyloid in the AD brain may be partly 
responsible for the destruction of neurites, thereby 
contributing to the formation of neuritic plaques and 
to neuronal death.
2 6
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Chapter 3
Amyloid 13 peptide Synthesis, Purification, and
Identification
In order to study the biological effect of 13 
amyloid protein and its interaction with a mouse 
neuroblastoma cell line, a synthetic fragment of BAP, 
Bl-40, was needed. This peptide was synthesized using 
an automated solid phase peptide synthesizer. This 
chapter briefly describes the synthesis, purification, 
and identification of Bl-40.
3-1. The general scheme of peptide synthesis
There are two ways to chemically synthesize a 
peptide: solution synthesis or solid phase synthesis.
In solution synthesis, a peptide is assembled from its 
amino terminus to its carboxyl terminus. One amino acid 
at a time is added and separation procedures are needed 
after each step in the synthesis to remove excess 
reagents and by-products. In solid phase peptide 
synthesis, the carboxyl terminal amino acid is 
covalently attached to an insoluble support by its 
carboxyl group, and therefore immobilized. Peptide 
chains are assembled from the carboxyl terminus,
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working towards the amino terminus. The development of 
solid phase peptide synthesis procedures greatly 
simplifies the process of peptide synthesis because all 
intermediate purification steps are essentially 
eliminated. Excess reagents and reaction by-products 
are washed away from the support-bound synthesizing 
peptide. Solid phase synthesis also avoids some of the 
problems that might be created by peptide insolubility.
The commercially available solid supports for 
peptide synthesis include polystyrene and polyamide- 
Kieselguhr supports. For this study, the Bl-40 was 
synthesized on PepSyn K (MilliGen/Biosearch, 
Burlington, MA, USA), which is a polyamide-Kieselguhr 
type peptide synthesis support consisting of a 
polyacrylamide gel polymerized within the pores of 
rigid macroporous kieselguhr particles (diatomaceous 
earth). The rigid framework of the kieselguhr particles 
provides a noncompressible support that retains the 
open channels necessary for rapid diffusion of 
reactants throughout the matrix. There is also no 
significant change in bed volume when reagents are 
changed during synthesis, and a continuous flow process 
is allowed. The polyacrylamide gel within the pores of 
Kieselguhr particles is formed by copolymerization of
2 8
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dimethylacrylamide with cross-linking monomers and 
functiona1izing compounds. The latter, sarcosine methyl 
ester, react with linker molecules to form primary 
amines, and provide the sites of attachment for the 
growing peptide.
In solid phase peptide synthesis, when the first 
C-terminal amino acid is attached to an immobilized 
support via its carboxyl group, its a-amino group is 
temporarily protected to prevent unwanted side 
reactions during amino acid-support coupling. After the 
coupling reaction, the amino terminus of support-bound 
amino acid is deprotected by basic cleavage of the 
protecting group. Next, after washing, the second amino 
acid with an activated carboxyl group and protected 
amino group is added. The deblocked amino terminus of a 
support-bound amino acid reacts with the activated 
carboxyl group of the incoming amino acid, resulting in 
the formation of a peptide bond. The peptide elongates 
by one amino acid. In each of the peptide synthesis 
cycles, the a-amino group of the incoming amino acid is 
temporarily protected at addition, to avoid side 
reactions during peptide bond formation. After this 
amino acid is assembled to the synthesizing peptide, 
its a-amino group protection is removed, the
29
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deprotected N-terminus of support-bound synthesizing 
peptide is then ready for the reaction with the next 
amino acid. Figure 3-1 shows the general scheme of 
peptide synthesis. The process of deprotecting the 
amino terminus of support-bound peptide, activating the 
carboxyl terminus of incoming amino acid, and 
performing the coupling reaction with the next amino 
acid, is repeated until the peptide is completed.
If the amino acid has a chemically active side 
chain group, It will also need to be protected in order 
to avoid participation of the reactive group during 
chain assembly. At the completion of peptide synthesis, 
the side chain protecting groups are removed and the 
synthesized peptide is cleaved from the support. The 
peptide is then subjected to further purification and 
identif ication.
3-2. Fmoc strategy of peptide synthesis: a-amino group 
protection
During peptide synthesis, the protection for a- 
amino groups and side-chain amino groups need to be 
distinguishable, so that the a-amino protection can be 
selectively removed before the coupling reaction in 
each peptide synthesis cycle, while keeping the side
30
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Attach first amino acid to the support
1
— ) Deblock amino protecting group
Wash to rem ove excess
Activate incoming amino acid
Couple to support-bound amino acid
Wash to remove excess
Cleave from the support & 
Deprotect side chain protection
Figure 3-1.General peptide synthesis schem e
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chain protection intact. The two most widely used 
methods of protecting an a-amino group in solid phase 
peptide synthesis are the Boc-benzyl strategy and the 
Fmoc-tBu strategy.
The framework for the solid-phase peptide 
synthesis using the Boc-benzyl strategy originated more 
than 30 years ago (Merrifield, 1963). The method is 
based on the differential acid lability of an a-amino 
protecting group and the side chain protecting groups. 
The acid labile t-butyloxy carbonyl group (Boc) is used 
in a-amino protection, and benzyl derivatives are used 
for side chain protection. The Boc-benzyl strategy uses 
the differential strength of acids to selectively 
remove the temporary a-amino protection during the 
repetitive synthesis cycles and the final side-chain 
deprotection at the completion of synthesis. Usually 
trifluoroacetic acid (TFA) is used in removing a-amino 
protection and HF is used to deblock side chain groups 
when peptide synthesis is completed.
The Fmoc-tBu synthetic strategy in solid phase 
peptide synthesis was introduced simultaneously by two 
groups (Chang and Meienhofer 1978; Artherton et al., 
1978). A clear distinction between the Fmoc-tBu 
strategy and the Boc-benzyl strategy is the adoption of
32
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the base-labile 9-fluorenyl methoxy carbonyl (Fmoc) 
group as the a-amino protecting group. The acid labile 
tertiary-buty1 (tBu) derivatives are used for side 
chain protection. The amino Fmoc protecting group can 
be rapidly removed by ft-elimination with secondary 
amines such as piperidine or other nucleophilic bases. 
The side chain protecting groups and peptide-support 
links, which are acid labile, are totally stable to 
peperidine during peptide synthesis. Amino acid side 
chain protecting groups are cleaved by 25-90% TFA when 
peptide assembly is completed.
3-3. Carboxyl group activation and side chain 
protection in Fmoc peptide synthesis
The activation of an amino acid is an essential 
step in the assembly of peptide chains because simple 
alkyl esters on the incoming amino acid undergo 
aminolysis at too slow a rate to be generally useful 
for peptide bond synthesis. Phenyl esters of amino 
acids are more active leaving groups, especially if 
electronegative substitutes are present on the aromatic 
ring. Examples of phenyl esters are -OPfp (penta- 
fluorophenyl) ester derivatives and -ODhbt (l-oxo-2- 
hydroxy-dihydrobenzo-triazine) ester derivatives. In
33
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the process of activation, the electron density around 
the carboxylate carbon is altered, making it 
susceptible to nucleophilic addition by the amino 
terminus of the support-bound peptide chain. After the 
amino protecting Fmoc group is removed by piperidine 
from the amino terminus of support-bound synthesizing 
peptide, the incoming amino acid with an activated 
ester group is added. Most amino acids are used as the 
solid -OPfp derivatives. Threonine and serine, however, 
are used in the -ODhbt form, since it is impractical to 
handle their -OPfp derivatives which are viscous oils. 
HOBt (1-hydroxybenzotriazole hydrate) is commonly used 
as a catalyst in acylation reaction to increase the 
efficiency of peptide bond formation
(MilliGen/Biosearch 1991).
Side chain protection is employed to avoid 
unwanted side reactions during peptide synthesis. 
Tertiary-buty1 ether (tBu) and tertiary butyl ester 
(OtBu) are typical protecting groups for threonine, 
tyrosine, serine, asparate, and glutamate. The 
tertiary-butyloxycarbony1 (tBoc) protection group is 
used for the routine protection of lysine and 
histidine. Figure 3-2 shows a general structure of Fmoc 
- amino acid - OPfp, an amino acid with its a-amino
34
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Figure 3-2. Structure o f  Fmoc-am1no ac1d-0Pfp. S t ru c tu re s  
o f  s1de-cha1n protected Fmoc-glutarate-OPfp and Fmoc-lyslne 
-OPfD.
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group in protected form and its carboxyl group in 
activated form. Side chain protecting groups -OtBu and 
-Boc are also shown in the examples of glutamic acid 
and lysine.
3-4. Amyloid fll-40 synthesis, cleavage, and 
deprotection
In this study, amyloid Bl-40 peptide was 
synthesized on a MilliGen/Biosearch 9050 Peptide 
Synthesizer, using the solid phase Fmoc-tBu strategy. 
The amino acid sequence of Bl-40 is:
H2N-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr- 
Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala- 
Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile- 
Gly-Leu-Met-Val-Gly-Gly-Val-Val-COOH 
The PepSyn Valine-KA resin, all reagents, and all 
amino acids in their Fmoc -amino acid -OPfp or Fmoc - 
amino acid -ODhbt form with side chain protection were 
purchased from MilliGen/Biosearch, Division of 
Millipore (Burlington, MA, USA).
Since the solid phase peptide synthesis started 
from the C-terminus of the peptide, the first C- 
terminal amino acid of Bl-40, Fmoc-valine, was 
covalently attached to PepSyn KA resin via its carboxyl
36
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group. About 1.5 gram of PepSyn Valine-KA 100 holding 
0.1 mmole of valine was packed into a column and 
connected to the peptide synthesizer.
When 20% piperidine in DMF (dimethylformamide) 
was flushed through the column, the a-amino protecting 
Fmoc group of valine was cleaved. The excess piperidine 
was removed from the system by washing with DMF. The 
second amino acid at the C-terminus of Bl-40 in its N- 
protected and C-activated derivative, a Fmoc-valine- 
Opfp, was then dissolved in a solution containing 0.3 M 
HOBt as a catalyst. Four millimole amino acid 
derivative to each millimole support-bound valine was 
injected into the system in this step to guarantee 
efficient coupling. When the second amino acid was 
coupled to the a-amino group of support-bound valine, 
the peptide chain was elongated by one amino acid. The 
cycle was repeated until completion of synthesis of Bl- 
40 peptide.
During the entire synthesizing process, the on­
line post-column detector enabled continuous 
spectrophotometric monitoring of the progress of 
peptide assembly. A typical post-column trace for one 
and a half cycles of amino acid addition and 
deprotection is shown in Figure 3-3. A sharp
37
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Figure 3-3. A typical peptide synthesis cycle monitored 
with the absorbance at 365 nm.
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deprotection peak was observed when the Fmoc group was 
released from the amino terminus of the synthesizing 
peptide during the piperidine wash. After the 
deprotection peak, strong absorption was caused by the 
addition of the Fmoc-amino acid derivative, which was 
followed by a series of oscillating peaks as the 
reactant was recirculated until the column and the 
system reached a uniform concentration. The removal of 
extra free amino acid derivatives by washing the column 
with DMF and directing the flow to waste was observed 
by the sharp fall in absorbance. At this point, the N- 
terminal deprotection for the next cycle was ready to 
start. The consistent area of deprotection peaks 
indicated that the assembly was proceeding smoothly.
The total amyloid Bl-40 peptide contained 40 amino 
acid residues; and the synthesis took 39 cycles. The 
side chain deprotecion of Fmoc-tBu peptide was achieved 
using TFA. The Fmoc-tBu strategy limits exposure to 
acid to the last event of synthesis, i.e., the 
liberation of the tBu type of protecting groups from 
the side chain and the peptide from the support at the 
completion of the peptide assembly. A conventional 
deblocking protocol for a synthetic peptide without 
Arg, Trp, Cys, Met, or Tyr is achieved by incubating
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the synthesized peptide with TFA: water (95:5 v/v) for 
one hour.
The Bl-40 sequence also includes amino acid 
residues of Arg, His, Tyr, and Met. Since it is 
difficult to remove the arginine side chain protecting 
group (4-methoxy-2,3,6-trimethylbenzenesulfonyl group), 
extended reaction time is required. On the other hand, 
methionine and histidine are readily deblocked of their 
side chain protecting groups in TFA, and are labile to 
free radical attack under acid conditions. To minimize 
side reactions, a low concentration of scavengers such 
as thiol (ethanedithiol and thiophenol) and sulfide 
(thioanisole or dimethylsulfide) were added to the 
deblocking reagent TFA.
After Bl-40 synthesis was complete, the peptide- 
support was taken from the synthesizer and unpacked 
from the column. The peptide-support was vacuum dried 
overnight and then incubated with cleavage reagent 
containing 90% TFA, 5% thioanisole, 3% ethanedithiol, 
and 0.01% methionine for 12 hours. The peptide- 
containing TFA solution was filtered and the filtrate 
was mixed with 7 times excess ethyl ether. A white 
precipitate was observed immediately, and the ether- 
peptide solution was incubated at 4°C overnight to
4 0
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allow complete precipitation. The precipitated peptide 
was collected by centrifugation, washed with ethyl 
ether and dried under vacuum for 6 hours.
3-5. Purification and identification of synthesized Bl- 
40 peptide
The precipitated Bl-40 was dissolved in 20 ml of 
5% acetic acid and then lyophilyzed to remove traces of 
organic solvent. The peptide was redissolved in a small 
volume of 5% acetic acid, and desalted by passing 
through a Bio-Rad (Hercules, CA, USA) Econo-Pac 10 DG 
gel filtration column.
Amyloid Bl-40 peptide contains only one tyrosine 
and three phenylalanines in its sequence. Its
absorption at 280 nm is relatively low compared with 
its absorption at 210 nm. However, 210 nm could not be 
used to detect the presence of synthesized B peptide in 
gel filtration eluates, because the eluting buffer of 
acetic acid also absorbs strongly at wavelengths of 200 
nm to 220nm. Figure 3-4 compares the absorbance of the 
eluating buffer and the absorbance of Bl-40 peptide 
over the wavelength range of 190 nm to 280 nm. The 
maximum absorption of acetic acid is at 215 nm. The 
absorbance drops very sharply and approaches zero at
41
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Figure  3 - 4 .  UV a b s o r b a n c e s  of a c e t i c  
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255 nm. Amyloid Bl-40 peptide absorbs most strongly at 
195 nm. The absorption then slowly decreases. Between 
245 nm to 230 nm, the asbsorbance of Bl-40 peptide is 
greater than that of acetic acid. Therefore, 254 nm was 
chosen to detect the presence of Bl-40 peptide in the 
eluates from the gel filtration column.
When fractions from the gel filtration column were 
monitored for their absorbances at 254 nm, a large peak 
containing synthesized peptide was obtained (Figure 3­
5) . The fractions containing the peptide were pooled, 
lyophilyzed, and dissolved in 2 ml buffer containing 
20% acetonitrile in 0.1% trifluoroacetic acid (TFA). 
After passing through a 0.5 \x filter to remove 
undissolved impurities, 5 ^1 of the synthetic peptide 
solution were injected into a 0.46x25cm reverse phase
HPLC Vydac (The Separations Group, Hesperia, CA, USA)
C4 column. The column was eluted by a gradient of
acetonitrile using a mixture of buffer A and B at a 
flow rate of 1 ml/min. Buffer A contains 20%
acetonitrile in 0.1% TFA while buffer B is 80% 
acetonitrile in 0.1% TFA. Elution of the peptide 
component was monitored by the UV absorbance at 214 nm. 
Figure 3-6 shows a major peak of synthesized peptide at 
a retention time of 22.6 minutes. Several HPLC runs
43
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Figure? 3 ”) Gel filt.rat.ion chromatograph 
of the synthesized / 3 1 - 4 0  peptide on Bio- 
Bad licoiio Pac 10DG column.
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Lieu re 3-6 .  HPLC purification of the s v n -  
i iie>i/.e ( I f i  { -40 peptide. Buffer A: 20% a c e -  
i on it rile in 0.1“ TFA, Buffer B: 80% a ce t o ­
nitrile in 0.1 % TFA.
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with 100 jul injections were performed to purify the 
synthesized 61-40 peptide.
The synthesized 61-40 peptide was further 
characterized by amino acid analysis. A 50 jul HPLC 
fraction of the peptide peak was hydrolyzed with 6 N 
HC1 at 110°C for 20 hours. The amino acid composition 
was analyzed using a Beckman 6300 Amino Acid Analyzer. 
Table 3-1 compares the amino acid composition of 
synthesized peptide with that expected from a 61-40 
sequence. The synthesized peptide has the correct 
amounts of alanine, phenylalanine, arginine, histidine, 
serine, valine, lysine, leucine, and methionine. Four 
aspartic acids are detected in the hydrolysis of 
synthesized peptide, matching the three aspartic acid 
and one asparagine residues in the 61-40 sequence. This 
pattern is obtained because asparagine is hydrolyzed to 
aspartic acid during acid hydrolysis. The number of 
glutamic acids detected in the peptide hydrolysis 
matches the total of glutamic acid and glutamine in the 
61-40 sequence. Due to the destruction of tyrosine 
during acid hydrolysis, the tyrosine residue in the 61­
40 sequence is not seen in the hydrolysis products of 
synthesized peptide. A slightly low level of isoleucine 
in the synthesized peptide could be explained by
4 6
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Table 3-1. Comparison of amino acid compositions 
between synthesized 6 peptide and the 61-40 sequence
4 7
Amino Acid 61-40 Sequence Synthesized Peptide
Aspartic acid 3 4
Asparagine 1 0
Glutamic acid 3 4
Glutamine 1 0
Alanine 3 3
Phenylalanine 3 3
Arginine 1 1
Histidine 3 3
Serine 2 2
Glycine 6 7
Tyrosine 1 Trace
Valine 6 6
Lysine 2 2
Leucine 2 2
Isoleucine 2 1
Methionine 1 1
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incomplete hydrolysis to the more resistant (hindered) 
peptide bound of Ile-Ile in Bl-40. Therefore, the amino 
acid compositions of the synthetic peptide and the Bl- 
40 sequence match very well, except for a slightly high 
level of glycine in the hydrolysis of synthesized 
peptide.
Immunochemistry studies also indicated that the 
synthesized Bl-40 peptide was recognized by an antibody 
against BAP using a dot blot assay. The synthesized 
peptide was not cross-reactive with an antibody against 
the C-terminal of BAPP. Thus, both amino acid 
composition analysis and immunoreactivity studies 
indicated the Bl-40 peptide was correctly synthesized.
48
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
49
A Heparin-binding Protein from Mouse Neuroblastoma 
Cells Shows Immunoreactivity to Antibody Against 
the B Amyloid Precursor Protein.
Chapter 4
4-1. Introduction
Mammalian cell surfaces and the surrounding 
extracellular matrix are rich in a wide variety of
glycoconjugates, including heparin (Hughes, 1983). 
Heparin interacts with a variety of proteins such as 
fibronectin (Hayashi et al. , 1980), endothelial cell
growth factor (Klagsbrun and Shing, 1985) , neural cell 
adhesion molecule (Cole and Glaser, 1986) and Alzheimer 
6 amyloid precursor protein (Schubert et al. , 1988;
Snow and Wight, 1989) . Heparin also binds to a class of 
low molecular weight proteins whose activity is more 
lectin-like (Eloumami et al., 1990).
On the basis of its structure, it has been
suggested that 6 amyloid precursor protein is a 
transmembrane glycosylated protein (Schubert et al., 
1989; Weidemann et al., 1989). Northern blot analysis
indicates that B amyloid precursor protein is present 
in a variety of tissues (Tanzi et al., 1988). There are 
several isoforms of B amyloid precursor protein,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
generated by alternatively spliced RNA, leading to a 
membrane bound form (Dyrks et al. , 1988; Mita et al. ,
1988) , a form which is secreted by various cultured 
cells, and a form that has proteinase inhibitor 
activity (Castro et al. , 1990; Smith et a l. , 1990).
Different molecular weights have been described for 
these precursor isoforms based upon antibody 
recognition. These cross-reactive proteins have ranged 
in molecular weight from 135 to 90 Kd (Weidemann et 
al . , 1989; Selkoe et al. , 1988). Attempts to
characterize the amyloid precursor protein in cultured 
cells have been limited to myelogenous leukemia (H562), 
lymphocytoma (U937) and monkey kidney cells as well as 
PC12 cells (Auti1io-Gambetti et al., 1988; Schubert et
al ., 1988). In cultured human fibroblasts and a human
neuroblastoma cell line, Dewji et al. (1990) reported
that the cellular form of the precursor appears to 
undergo amino-terminal processing yielding many smaller 
fragments, whereas the secreted form does not show any 
proteolytic cleavage after its release from the cell 
surface. The study described in this chapter extended 
these works to include the mouse neuroblastoma cell 
line NB41A3 (Zhao et al., 1991a).
50
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4-2. BAPP C-terminal peptide synthesis, purification, 
and identification
A BAPP C-terminal peptide (C-peptide) was 
synthesized using the method described in Chapter 3. 
Figure 4-1 demonstrates the amino acid sequence of the 
C-peptide located in the cytoplasmic domain of BAPP, 
containing residues 674-693 of BAPP695. Its amino acid 
sequence is: NH2-Leu-Ser-Lys-Met-Gln-Gln-Asn-Gly-Tyr-
Glu-Asn-Pro-Thr-Tyr-Lys-Phe-Phe-Glu-Gln-Met-COOH.
After peptide synthesis, the C-peptide was 
purified on a Bio-Rad Econo-Pac 10 DG gel filtration 
column (Bio-Rad Laboratories, Hercules, CA, USA). The 
first and also the major peak of the gel filtration 
chromatograph contains the synthesized C-peptide. The 
other two small peaks are fragments of synthetic 
peptide (Figure 4-2) . Fractions 3 to 8 in the major 
peak were pooled together and subjected to amino acid 
analysis. When the amino acid composition of 
synthesized C-peptide is compared with that expected 
from its sequence, the synthetic C-peptide had the 
correct amount of threonine, serine, proline, glycine, 
leucine, phenylalanine, and lysine (Table 4-1). Due to 
the deamination of asparagine to aspartic acid in acid 
hydrolysis, the hydrolysis products of synthetic C-
51
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Figure 4-1. Demonstration of the BAPP C-terminal amino acid sequence. Black box indicates 
BAP region. Open box indicates the synthetic BAPP C-peptide sequence containing 20 amino 
acids. The amino acid sequence of the entire BAPP cytoplasmic domain is shown.
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Figure 4-2..  Gel filtration purification of 
the synthesized /SAPP C- terminal  peptide 
on Rio Rad Econo-Pac 10 DG column. 
Fractions 3-8  were used in amino acid 
analysis and antibody produaction.
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Table 4-1. Comparison of amino acid compositions 
between synthesized C-peptide and its native sequence.
54
Amino Acid BAPP C-Peptide 
Sequence
Synthesized C- 
Peptide
Aspartic acid 2
Asparagine 2
Glutamic acid 2 4
Glutamine 3
Phenylalanine 2 2
Serine 1 1
Glycine 1 1
Tyrosine 2 1
Lysine 2 2
Leucine 1 1
Methionine 2 1
Threonine 1 1
Proline 1 1
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peptide showed two aspartic acids, matching the two 
residues of asparagine in the C-peptide seguence. The 
two glutamic acids and three glutamine residues in 
synthetic peptide should result in five glutamate 
residues after acid hydrolysis. Because of the large 
size of the glutamate peak compared to other amino acid 
residues, the integration of glutamic acid gave a 
relatively low value. The amino acid analysis indicated 
4.37 glutamic acids in the hydrolysis products of 
synthetic C-peptide, slightly lower than the expected 
five glutamic acids from C-peptide sequence. The 
methionine and tyrosine were partially destroyed during 
acid hydrolysis, explaining their lower than expected 
values. Based on the amino acid analysis data, the BAPP 
C-terminal peptide was judged to have the correct 
sequence.
4-3. Preparation of anti - C-peptide antibody and 
characterization of the antibody's specificity
The Imject SuperCarrier EDC System for Peptides 
(Pierce Chemical Co. , Rockford, IL, USA) was used for 
antigen preparation. Two milligrams of synthesized C- 
peptide were reconstituted in 0.5 ml of conjugation 
buffer containing 0.1 M MES (2-(N-Morpholino)-
55
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ethanesulfonic acid), 0.9 M NaCl, 0.02% sodium azide, 
pH 4.7. The peptide solution was then added to 0.2 ml 
of a carrier protein solution containing 2 mg of 
cationized BSA. The peptide - carrier protein 
conjugation reaction was carried out for 2 hours at 
room temperature. The reaction mixture was separated on 
a G-25 gel filtration column and the eluates were 
monitored at 280 nm on a UV spectrophotometer (Figure
4-3) .
The adjuvant, Imject Alum (aluminum hydroxide; 45 
mg/ml), was added drop-by-drop alternating with 
stirring to the conjugate solution to reach the final 
Alum concentration of 11.2-22.5 mg/ml. After stirring 
for 30 minutes, the mixture was filtered through a 0.2 
u sterile cellulose acetate membrane filter and 0.1 ml 
of immunogen filtrate (approximately 0.04 mg of 
peptide) was injected into several sites on the back of 
a rabbit. The rabbits were boosted again with an 
equivalent amount of antigen at day 14. Blood was drawn 
one month after the initial injection and allowed to 
clot for 13 hours at 4°C. Serum was separated from the 
clot by centrifugation for 30 minutes at 2000xg.
The specificity of the anti-C antibody was tested 
in a dot blot experiment. About 40 /ig synthetic BAPP
56
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Fieure 1 3. Gel filtration chromatograph of
I lie (' peptide - carrier protein conjugates.
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C-terminal peptide and 66-25 peptide, respectively, 
were dot blotted to Immobilon transfer membranes 
(Millipore Corp., Bedford, MA, USA) by applying a 
vacuum using a MilliBlot-S system (Millipore Corp.). 
Sections of the membrane were incubated either with 
anti - C-peptide antibody or with a pretreated anti-C 
antibody, which had been mixed with the synthetic C- 
peptide or 66-25 peptide overnight and immuno- 
precipitates removed by centrifugation.
If the antibody recognizes the C-peptide 
specifically, the pretreatment of an antibody with 
synthetic C-peptide would block an antibody's binding 
sites and therefore inhibit its ability to bind C- 
peptide in the dot blot experiment. The results are 
shown in Table 4-2. The preparation of anti-C antibody 
recognized synthetic BAPP C-terminal peptide. 
Preincubation of the antibody with synthetic C-peptide 
abolished the antibody's ability to recognize C-peptide 
on a dot blot test, indicating the antibody - C-peptide 
reaction was specific. The anti-C antibody did not 
recognize 66-25 peptide and the preincubation of the 
antibody with synthetic 66-25 peptide had no effect on 
the dot blot immunoreactivity. These results indicate 
that the anti - C-peptide antibody recognizes the C-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Table 4-2. Specificity test of anti-BAPP C-peptide
antibody.
Dot Blot Site 1 Site 2 Site 3 Site 4
Sample: C-peptide C-peptide C-peptide <36-25
peptide
Antibody: Anti-C
antibody
Anti-C 
antibody 
pretreated 
with C- 
peptide
Anti-C 
antibody 
pretreated 
with <36-25 
peptide
Anti-C
antibody
Result: (++++) (+) (++++) (-)
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terminal peptide of 6APP and it does not cross react 
with the amyloid region of the precursor protein.
4-4. Anti-C immunoreactivity of neuroblastoma membrane 
extract and conditioned medium of cultured cells
Cultures of mouse neuroblastoma cells (NB41A3) 
were obtained from American Type Culture Collection 
(Rockville, MD, USA) and cultured at 37°C in a 5% C02 
humidified incubator in HL-1 medium (Ventrex 
Laboratories, Inc., Portland, ME, USA), which is a 
modified DME:F12 medium (See Appendix I), containing 
2.5 mM Glutamine, 50 units/ml penicillin and 50 jug/ml 
streptomycin. Two groups of neuroblastoma cells were 
cultured in HL-1 medium either with or without a 
supplement of fetal calf serum (FCS). Conditioned 
medium (CM) was obtained by removing neuroblastoma 
cells via centrifugation, while neuroblastoma cell 
membrane proteins were extracted as described in 
section 4-5 using the modified protocol of Smith et 
al., 1990.
Both the neuroblastoma membrane extract and the 
conditioned medium of cultured cells were blotted on an 
Immobilon transfer membrane and tested for their anti-C 
immunoreactivity as described previously. Synthetic C-
6 0
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peptide was used as a positive control in this 
experiment. As shown in Table 4-3, the FCS-supplemented 
cell culture medium was slightly cross reactive with 
anti-C antibody; cell culture medium without FCS 
supplement was not recognized by the antibody. 
Therefore, any anti-C immunoreactivity present in FCS- 
free neuroblastoma conditioned medium should come from 
cultured neuroblastoma cells. The neuroblastoma cells 
released a small amount of anti-C immunoreactive BAPP 
fragments into the cell culture medium.
The FCS-free neuroblastoma conditioned medium was 
also tested using a Mini-Protein II Multi Screen 
Apparatus (Bio-Rad Laboratories, Hercules, CA, USA) 
v/ith anti-628 (Fraser et al. , 1991), anti-substance P
(Sigma Chemical Co. , St. Louis, MO, USA) , and anti- 
Kunitz inhibitor antibodies (Sigma Chemical Co.). Only 
anti-628, which recognizes residues 1-28 of the 6 
amyloid region, showed a positive reaction. NB41A3 
cells released fragments of 6APP containing the C- 
peptide and 61-28 sequences into the conditioned 
medium. However, most anti-C immunoreactivity was 
retained in the cell membrane fraction.
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Table 4-3. Anti-C immunoreactivity of neuroblastoma 
membrane protein and conditioned medium
Dot Blot Site 1 Site 2 Site 3
Sample: C-peptide HL-1 Medium HL-1 Medium
w/o FCS w/ FCS
Antibody: Anti-C Ab Anti-C Ab Anti-C Ab
Result: (++++) (-) ( + )
Site 4 Site 5 Site 6
Sample: NB extraction CM w/o FCS CM w/ FCS
Antibody: Anti-C Ab Anti-C Ab Anti-C Ab
Result: (+++) ( + ) ( + )
FCS: Fetal Calf Serum; CM: Conditioned Medium, NB:
Neuroblastoma membrane extract; ( + ) : Positive result;
(-): Negative result.
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4-5. Neuroblastoma membrane protein extraction and 
separation by heparin affinity chromatography
Neuroblastoma cells were grown for three days 
until confluent. The cells were scraped from the flask 
and washed free of medium with phosphate buffered 
saline (PBS) containing 10 mM phosphate and 150 mM 
NaCl, (pH 7.2). The cell pellet was homogenized in an 
extraction buffer containing 10 mM phosphate, 2.5 mM 
PMSF (phenylmethylsulfonyl fluoride) at pH 7.2 using a 
tight-fitting Dounce homogenizer. After centrifugation 
for two hours at 100,000xg, the soluble fraction was 
removed and the pellet was homogenized in PBS 
containing 1% Triton X-100 and 2.5 mM PMSF. The Triton 
X-100 homogenate was centrifuged at 20,000xg for 30 
minutes. The soluble fraction contained neuroblastoma 
cell membrane-associated protein (Smith et al., 1990). 
Lipids in the Triton X-100 soluble fraction were 
removed by extraction with 5 volumes of 
hexane:isopropyl alcohol (3:2). The protein content in 
the neuroblastoma membrane extract was determined as 10 
mg by the MicroBCA method (See Appendix II).
Five mg of neuroblastoma membrane protein extract 
were loaded on top of a 13x2.5cm column containing 50 
ml of heparin-agrose (binding capacity = 800 jig
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heparin/ml gel). The column was equilibrated with 0.01 
M Tris-HCl (pH 7.0) containing 0.15 M NaCl (TBS) and 
unbound protein was washed out with TBS. The heparin- 
binding protein was eluted using a higher salt 
concentration, 1.0 M NaCl in 0.01 M Tris-HCl buffer (pH 
7.0). The flow rate was 15 ml/hour. Figure 4-4 
summarizes the neuroblastoma membrane protein 
separation procedure.
Collected fractions from heparin affinity 
chromatography were monitored for their absorbance at 
280 nm (Figure 4-5). The large protein peak in Figure
4-5 was heparin-nonbinding and was washed through the 
column by 0.15 M NaCl in TBS. After the non-bound 
proteins passed through, the heparin-binding proteins 
eluted with 1.0 M NaCl were observed as a smaller peak. 
Fractions from each peak of heparin affinity 
chromatography were combined separately, desalted by 
concentrating on an ultrafiltration membrane PM 10 
(Amicon, Inc., Beverly, MA, USA) and total protein 
concentration was determined. Thirty percent of the 
protein was recovered after heparin affinity 
chromatography (Table 4-4). The yield of heparin- 
binding proteins was 0.4 mg, which was 8.1% of the 
total membrane proteins loaded to the column.
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Cultured neuroblastoma cells
Wash with protein extraction buffer
Homogenisation
Cytosolic fraction
100,000g, 2 hours
Membrane fraction
Homogenization in l% T ri to n X - 1 0 0
20,000g, 30 min.
Supernatant Pellet
Hexane :isopropyl alcohol 
wash to remove lipid
Neuroblastoma membrane protein
Hep arin affinity chromatography
Heparin-binding protein Heparin-unbound protein
F igu re  h-4 .  Neuroblastoma membrane p ro t e in  
e x t r a c t i o n  p r o t o c o l .
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Figure 4 f>. Heparin af f in i ty  c h r o m a t o g r a p h  of neurobl as t  o ma
m e m b r a n e  e x t r a c t .  Un b o u n d  p ro t e i ns  were  r e mo v e d  wi th O.lf)
M NaCl in Tris —HC1 buffer ,  pH 7.2. Heparin binding pro t e i ns  
were  e l u t e d  with 1.0 M NaCl in Tris —MCI buffer.
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Table 4-4. Protein yield of heparin affinity 
purification of neuroblastoma membrane protein.
Protein Percentage
(mg) Recovery
NB membrane extract 4.94 100
Heparin-unbound protein 1. 08 21.9
Heparin-binding protein 0.40 8.10
NB: neuroblastoma cells.
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4-6. SDS-polyacrylamide gel electrophoresis and western 
blot analysis of neuroblastoma protein
SDS-polyacrylamide 9.0% separating gels and 4% 
stacking gels were prepared following the Bio-Rad Mini- 
Protean II Dual Slab Cell Instruction Manual (See 
Appendix III).
Neuroblastoma membrane proteins were separated on 
SDS-gels using a Bio-Rad Dual Slab Cell (Bio-Rad 
Laboratories, Hercules, CA, USA) at a constant setting 
of 200 volts. For each run of gels, one gel was stained 
with Coomassie Brilliant Blue, while the other gel was 
used for a western blot assay.
On dot blot analysis, samples were blotted to 
Immobilon transfer membranes by applying a vacuum to a 
MilliBlot-S system (Millipore Corp., Bedford, IL, USA). 
For western blot experiments, proteins were first 
resolved on SDS-polyacrylamide gel electrophoresis, and 
then electrophoretically transferred to Millipore 
Immobilon membranes by using a Bio-Rad Semi-Dry 
Electroblotter. When the Immobilon membrane containing 
the transfered samples is incubated with an antibody 
against the 6APP C-peptide, the antibody should bind 
the corresponding proteins. At the end of the western 
blot, a color complex will be developed at the location
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of the antibody - protein interaction (See Appendix 
IV) .
As shown in Figure 4-6, when the neuroblastoma 
membrane proteins were separated by SDS-PAGE, four 
major polypeptides were detected in western blots by an 
antibody against synthetic BAPP C-terminal peptide. 
These four major polypeptide bands had molecular 
weights of 89, 76, 60, and 41 Kd (Figure 4-6, Lane C). 
The antibody to the C-terminus of BAPP also detected 
several minor higher molecular weight polypeptide bands 
on the western blot. Anti-substance P and anti-Kunitz 
inhibitor antibodies did not recognize any bands on the 
blot, but the anti-C immunoreactive components were 
also immunoreactive with anti-B peptide antibody 
(results not shown).
On a dot blot experiment, only the heparin-binding 
fraction showed immunoreactivity to an anti-C antibody. 
The heparin-binding fraction was further resolved as 
three major polypeptides with apparent molecular weight 
of 89, 60, and 41 Kd upon SDS-PAGE (Figure 4-6. Lane
B) . Among them the 89 and 4 1 Kd bands show anti-C 
immunoreactivity on western blot (Figure 4-6. Lane D). 
These two bands have identical molecular weights when 
compared with the western blot of the neuroblastoma
69
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Figure 4-6. SDS-PAGE and western blot with antibody against 
the BAPP C-terminal peptide.
Lane A: SDS-PAC-E, NB membrane extract, Coomassie blue stain. 
Lane B: SDS-PAGE, NB membrane heparin-binding fraction.
Lane C: Western blot, NB membrane extract.
Lane D: Western blot, NB membrane heparin-binding fraction.
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membrane extract, which has two extra anti-C 
immunoreactive bands with molecular weights of 76 and 
60 Kd.
4-7. Amino acid analyses of heparin-binding and 
heparin-unbound proteins
Both heparin-binding and unbound neuroblastoma 
membrane proteins were subjected to acid hydrolysis and 
amino acid analysis. About 0.1 ml of each fraction were 
separately lyophilized in a small hydrolysis test tube. 
Each tube was then put into a vial containing 0.5 ml of 
6 N HC1. Together, they were subjected to a vacuum for 
10 minutes on a Waters Pico-Tag Vacuum Station 
(Millipore Corp.) followed by a 110°C incubation of 24 
hours. The products were analyzed on a Beckman 6300 
Amino Acid Analyzer (Beckman Instruments, Inc., Palo 
Alto, CA, USA).
Comparing the amino acid composition of 
neuroblastoma membrane heparin-binding protein with 
that of an unbound fraction, it appeared that most 
amino acids were present in both fractions in a similar 
ratio, while several polar amino acids were highly 
variable between the two fractions. Results in Table 4­
5 indicate that the levels of tyrosine and serine in
7 1
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Table 4-5. Amino acid analyses of neuroblastoma 
membrane heparin-binding and heparin-unbound proteins.
72
Amino Acid Heparin- 
binding (%)
Heparin- 
unbound (%)
BAPP last 100 
residues (%)
Asp/Asn 9. 79 9.23 8 . 00
Threonine 5.43 4.75 5.00
Serine 11.92 5.84 4 . 00
Glu/Gln 10 .80 14 .25 14.00
Proline 6 . 05 5.80 2.00
Glycine 8 . 86 7 . 77 8.00
Alanine 9 . 52 10. 86 6 . 00
Valine 9 . 30 7 .77 13 . 00
Isoleucine 3 . 62 3.30 6 . 00
Leucine 7 . 46 6.88 5 . 00
Tyrosine 2. 05 1. 09 4 . 00
Phenylanine 3 . 36 2. 62 5.00
Lysine 6. 11 11.79 7.00
Hisdidine 1. 72 1.61 6 . 00
Arginine 2 . 99 5 . 39 2 . 00
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the heparin-binding proteins were only about half of 
that in the heparin-unbound fraction, while lysine,
arginine, and glutamic acid levels in heparin-binding 
proteins were about 50% to 100% more than in the 
heparin-unbound fraction. The fourth column of Table 4­
5 compares the amino acid compositions of neuroblastoma 
membrane proteins with the last 100 residues at the C- 
terminus of BAPP. When analyzing the experimental data, 
however, one should keep in mind that the neuroblastoma 
membrane heparin-binding fraction contains many 
proteins, and some of them may not be related to BAPP 
or be immunoreactive to antibody against BAPP C- 
peptide. The aspartic acid level in heparin-unbound 
(9.79%) and heparin-binding (9.23%) fractions were
similar to the total of aspartic acid/asparagine in the 
last 100 residues of BAPP (8.00%). The glutamic 
acid/glutamine level in the last 100 residues of BAPP 
(14.00%) was close to that in heparin binding fraction
(14.24%) and was significantly higher than that in the
heparin-unbound fraction (10.80%). The serine level in 
C-terminal BAPP (4.00%) was also much closer to that in 
the heparin-binding protein (5.84%) than that in the 
heparin-unbound fraction (11.92%). However, the 
heparin-binding fraction had higher levels of
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positively charged amino acids. It contained 11.79% 
lysine and 5.39% arginine comparing to 7% lysine and 2% 
arginine at the last 100 residues of C-terminal SAPP. 
These high lysine and arginine components may come from 
the non-anti-C immunoreactive proteins in the heparin- 
binding fraction. The negatively charged sulfate groups 
on heparin could attract positively charged free 
lysines and arginines as well as the positively charged 
proteins. Therefore, the heparin-binding fraction could 
contain proteins that had high lysine and arginine 
level and were not immunoreactive with anti-C antibody.
4-8. HPLC analysis of neuroblastoma heparin-binding 
protein.
The heparin-binding fraction of neuroblastoma 
membrane protein was further analyzed by reversed-phase 
HPLC on a 4.6x250 mm Vydac C4 column (The Separations 
Group, Hesperia, CA, USA) using an acetonitrile 
gradient of 20% to 30% in 0.1% (v/v) trifluoroacetic
acid (TFA) at a flow rate of 1 ml/min. Protein 
absorbance was determined at 214 nm. Figure 4-7 shows 
the chromatographic profile where the heparin-binding 
fraction was separated by an acetonitrile gradient into 
two fractions. The first HPLC fraction consisted of
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Figure 4 - 7 .  Reverse  p h a s e  HPLC s e p a r a t i o n  of n e u r o b l a s t o m a  
m e m b r a n e  a s s o c i a t e  hepar i n  -  binding prote ins .  BOO //g prot ein 
in 500  / i l l were  i n jec t ed  into a Vydac 04 c o l u mn ,  buf fer  A: B0% 
a c e t o n i t r i l e  in 0.1% TFA, Buffer  B: 80% ac e t o n i t r i l e  in 0.1% TFA.
Flow r a t e  is 1 m l / m i n .
cn
several overlapping protein peaks with retention times 
ranging from 20 to 25 minutes. The second HPLC fraction 
contains one single peak with a retention time of 52.8 
minutes. These fractions were tested on a dot blot 
analysis using an antibody against BAPP C-peptide. 
Fraction 2 was cross-reactive with the antibody (result 
not shown).
4-9. Discussion
Brain tissue contains various heparin binding 
activities (Bladier et al. , 1989; Eloumami et al. ,
1990; Jessell et al. , 1990). Human Alzheimer amyloid
and the Alzheimer B amyloid precursor protein have been 
observed over the years to be associated with 
glycosaminoglycans (Snow et al., 1987; Glenner et al. ,
1984). Since neuroblastoma cells can show different 
morphological forms depending on growth conditions 
(Gurwitz and Cunningham 1990), it is worthwhile to 
characterize their heparin-binding proteins and look 
for any relationship with the amyloid precursor 
protein.
Polypeptides of 41, 60, and 89 Kd have been
purified from neuroblastoma cells using the heparin- 
binding purification protocol of Ceri et al . (1981).
7 6
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Since the cells were washed free of medium before 
homogenization, these proteins are associated with the 
cells. Their presence in the 100,000g pellet indicates 
that they are bound to the cell membrane. In the 
heparin-binding fraction, the 41 and 89 Kd proteins 
were immunoreactive with antiserum to the carboxyl 
terminal of the B amyloid precursor protein. The 
molecular weights of these polypeptides are lower than 
those reported for human fibroblasts where cross­
reactive bands with molecular weights of 228 and 130 Kd 
were seen in SDS gels (Autilio-Gambetti et a l . , 1988).
However, the molecular weights of these two 
polypeptides fall in the range of cellular BAPP 
fragments described by Dewj i et al. (1990) . We noted
that several minor higher molecular weight bands in the 
total cell membrane homogenate were also 
immunoreactive. No anti-carboxyl terminal
immunoreactive protein bands were seen in the heparin- 
unbound fraction. When we tested the heparin-binding 
fraction by dot blot analysis with an antibody to the 
BAP region of BAPP (anti-BAPP695 597-624); a positive 
reaction was observed. This would indicate that the 
last 100 amino acids of BAPP were present in these 
heparin-binding proteins and the fragment-generating
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
process occurred in the amino terminal half of the 
protein. Our identification of 89, 76, 60, and 41 Kd
immunoreactive proteins from neuroblastoma cells 
supported the observations of Simpson et al. (1989).
Using an antiserum raised to an extracellular domain 
(residues 556-566) of the SAPP, they reported the 
presence of 70 and 88 Kd proteins in western blots of 
Alzheimer's disease, Down's syndrome and control human 
brains. In an experiment using the Triton X-100 soluble 
fraction of PC12 cells, they observed a pattern similar 
to what we observed in the NB41A3 cells.
Recently, Castro et al. (1990) proposed that SAPP
may function as part of a feedback control mechanism 
that modulates the production of nerve growth factors.
It is possible that the presence or absence of 
different domains in the S amyloid precursor protein 
dictate the metabolic pathway involved in its 
processing. Simpson et al. (1989) reported that the 88
Kd protein was reduced in three out of six brains with 
Alzheimer pathology and they suggest that an imbalance 
between pathways may lead to amyloid deposits. In our 
study, the anti-C immunoreactive components were not 
reactive with anti-Kunitz antibody, indicating they may 
not contain Kunitz proteinase inhibitor sequences.
78
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The Toxicity and Interaction of a Synthetic Amyloid fll- 
40 Peptide with Mouse Neuroblastoma Cell Line NB41A3.
5-1. Introduction
Experimental studies have shown unexpected 
biological activities from the peptide products of 
degenerating neurons. Alzheimer li amyloid peptides may 
have neurotrophic effects in rat neuronal hippocampal 
cultures (Araujo and Cotman, 1992; Whitson et al. ,
1989; Whitson et al., 1990; Yankner et al., 1990b). At 
higher concentrations, neurotoxic effects have
positively been observed in rat cells (Yankner et al . ,
1990a; 1990b; 1989). The neurotoxicity of amyloid 8
peptide is potentiated by nerve growth factor (Yankner 
et al., 1990a) and, in turn, 6 amyloid peptide may 
potentiate the toxicity of glutamate in cultured 
cortical neurons (Koh et al., 1990; Mattson et al. ,
1992). Amyloid 6 peptide also increased neuronal 
susceptibility to injury by glucose deprivation (Copani 
et al. , 1991). Neurotoxicity has also been seen when
SDS-insoluble amyloid fractions, called amyloid cores, 
isolated from Alzheimer Disease brains were injected 
into the rat brain (Frautschy et al. , 1991). At the
7 9
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same time, Roher et al. (1991) have shown that isolated
6 amyloid peptide reduces the survival of sympathetic 
neurons in culture. Recently, Kammesheidt et al. (1992)
showed age related increases in the deposits of 3 
amyloid peptide immunoreactivity in transgenic mice
expressing the carboxyl-terminal fragment of the
Alzheimer amyloid precursor protein. The observation of 
abnormal appearing neurites in the CA2/3 region of the 
hippocampus of these transgenic mice supports the
correlation between amyloidogenesis and specific 
neuropathology. Similarly, Cai et al. (1993) showed
that human neuroblastoma cell line M17 transfected with 
a mutant 6 amyloid precursor protein gene released 6 
times more 6 amyloid peptide into the medium.
Although these studies have implicated 5 amyloid 
peptide in the neurodegenerative process, the mechanism 
of action is still unknown (Hardy and Higgins, 1992; 
Kosik, 1992; Mattson and Rydel, 1992a; Giordano et al., 
1994; Kowall, 1994). Besides excitotoxicity and
alterations in calcium homeostasis (Koh et al. , 1990;
Mattson et al. , 1992b; Hartmann et al. , 1994) other
possible mechanisms of 6 amyloid toxicity have been 
proposed in recent years, including membrane changes 
(Nitsch et al. , 1992 ; Arispe et al. , 1993), disruption
8 0
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of cytoskeletal transport (Grundke-Iqbal et al. , 1986;
Nukina et al., 1992 ; Caputo et al. , 1992), complement
activation (Rogers et al., 1992), free radical 
generation (Hensley et al. , 1994), and local acute
phase reaction (Abraham et al. , 1988; Griffin et al. ,
1989).
Since primary brain neuronal cultures are 
difficult to establish and inefficient for large-scale 
screening procedures, we wished to determine if BAP 
neurotoxicity could be assayed in other continuous 
neuronal cell lines using serum-free media. This 
chapter extends the 6 amyloid peptide neurotoxicity 
studies to a cultured mouse neuroblastoma cell line 
NB41A3, and discusses the mechanism of neuroblastoma- 
6AP interaction.
5-2. Amyloid 61-40 peptide synthesis and cell culture
Synthetic 61-40 peptide (See Section 3-4) was 
purified by gel filtration chromatography and HPLC (See 
Section 3-5) . An amino acid analysis and a dot blot 
analysis were used to verify that the synthetic 61-40 
has the expected amino acid composition and 
immunoreactivity. Cultures of mouse neuroblastoma cells 
were obtained from ATCC and cultured in HL-1 medium
8 1
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(Ventrex Laboratories, Inc., Portland, ME, USA) 
supplemented with 10% fetal calf serum (FCS) , 2.5 mM
glutamine, 50 units/ml penicillin and 50 ^g/ml
streptomycin (Sigma Chemical Co., St. Louis, MO, USA) 
in a 5% C02 humidified incubator.
After being washed with serum-free media, 
approximately 5000 cells were plated into each well of 
24 well plates. Control cells were plated in FCS-free 
medium only, while experimental groups were plated in 
FCS-free medium with varying concentrations of the 
synthetic Bl-40 peptide. In the experiments designed 
to study the albumin effect, neuroblastoma cells were 
cultured in FCS-free medium with bovine serum albumin 
(BSA) concentrations ranging from 0 to 200 /^g/ml.
Quadruplicates of each assay were performed.
5-3. The interaction of Bl-40 with mouse neuroblastoma 
cells: a toxicity assay
Three different assays for Bl-40 toxicity were
used:
1). Toxicity of synthetic Bl-40 was measured by 
observing changes in cell number. Twenty-four 
hours after plating the cells, 5 fields (0.708 mm2 
per field) were chosen from each well, and the
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cell number in each field was counted using a xl25 
inverse phase microscope. A low number of cells 
compared to the control in the field indicates 
slow cell growth.
2). Cell growth was also evaluated by change in total 
cell protein. Six days after plating the cells, 1 
ml of cell suspension was centrifuged. The 
resulting cell pellet was homogenized in one ml of 
PBS buffer. A 50 n1 sample was assayed for protein 
using the Pierce BCA Microprotein Assay Kit (See 
Appendix II) .
3). The release of a cytosolic enzyme, lactic 
dehydrogenase (LDH) , by cells into the cell 
culture medium was used as an indicator of cell 
death. An Oxford LK-100 Cytotoxicity Assay Kit 
(Oxford Biomedical Research, Inc., Rochester Hill, 
MI, USA) was used in this assay. After 
centrifugation to remove cultured cells, 100 jxl of 
conditioned media were mixed with 100 ill of LDH 
substrate, and incubated for one hour at room 
temperature. The reaction was stopped by adding 50 
111 1M HCl and the absorbance was measured at 492 
nm. Because only a dead cell releases its 
cytosolic LDH into the medium, the amount of LDH
83
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in the conditioned medium is proportional to the 
number of accumulated dead cells in the culture. 
This was denoted as LDH related to cell death 
(dLDH) . When the cell culture was incubated with 
cell lysing reagent for 1 hour, all the cells in 
the culture should be lysed. Thus the detected LDH
activity in the media is proportional to the total 
number of cells in the culture and is called tLDH. 
The difference between the tLDH and dLDH is the 
LDH released from the living cells (cLDH).
5-4. Cell growth curve
In order to examine if tLDH and dLDH truly reflect 
cell growth and cell death in the culture, a cell
growth curve was developed using LDH data. Figure 5-1
shows that tLDH, an indicator of the total number of 
cells in the culture, increases rapidly within the 
first week, representing the rapid cell growth in the 
exponential phase. After day 6, tLDH release reaches a 
plateau, indicating a stationary phase. The cell 
protein assay, another indicator of the total number of 
cells in the culture, gives a similar curve to that of 
the tLDH (data not shown). The cell death-related LDH, 
dLDH, is low in the first 5 days of the culture, but it
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rises rapidly after day 6 and eventually reaches the 
tLDH level at day 15, representing the cell death 
phase. The difference between tLDH and dLDH, which 
represents the number of living cells in the culture 
(cLDH), increases together with tLDH during the first 6 
days when cells are in the exponential growth phase, 
and then decreases when cell death rate rises rapidly. 
This typical cell growth curve presented by the LDH 
data suggests that cells are in the exponential growth 
phase up to day 5, and that tLDH and dLDH could be used 
to evaluate cell growth and cell death in the cultures.
5-5. Amyloid fi peptide toxicity to neuroblastoma cells 
cultured in FCS-free medium
When cells were cultured in serum-free medium with 
100 /Ltg/ml BSA, different cell growth rates were 
observed at various Bl-40 peptide concentrations. The 
cell number counts indicated that there were more 
living cells in the group without Bl-40 peptide in the 
medium. Cell protein and tLDH were also lower in the 
Bl-40 treated groups. The higher the amyloid Bl-40 
peptide concentrations, the lower the cell growth (as 
indicated by cell number) in the culture and the lower 
the cell protein and tLDH were (Figure 5-2) . These data
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confirm the lower cell growth in the Bl-40 treated 
cells and suggest that Bl-40 has a toxic effect on 
cultured neuroblastoma cells. Surprisingly, the 
indicator of cell death, dLDH, is also lower in the Bl- 
40 treated cells than in the control group. The 
implications of lower cell death (dLDH) in Bl-40 
treated cultures will be discussed later in this 
chapter in Section 5-8.
5-6. Bovine serum albumin stimulates neuroblastoma cell 
growth
In the absence of Bl-40 peptide, neuroblastoma 
cells were first cultured in a serum-free medium with 
varying BSA concentrations. Experimental data indicated 
that cells grew better in the presence of BSA. As shown 
in Figure 5-3, there was as much as a 20% increase in 
cell numbers and as much as 32% increase of cell 
protein in the groups where BSA was present.
A similar experiment was performed with 100 nM Bl- 
40 concentration. There was less overall cell growth in 
this experiment because of the addition of Bl-40 
peptide. However, a similar cell growth - BSA 
concentration relationship was observed (Figure 5-3),
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cell number increased up to 12% and total cell protein 
increased up to 21% in the presence of BSA.
At all tested BSA concentrations, BSA stimulated 
neuroblastoma cell growth despite Bl-40 peptides' 
presence. However, the trophic effect of BSA was less 
obvious when Bl-40 was added. In other words, the B 
peptide toxicity might be larger in the presence of 
BSA.
5-7. The effect of BSA on Bl-40 toxicity
If B amyloid peptide toxicity is evaluated as the 
percentage decrease of cell growth by comparing data 
from cultures with zero and 100 nM B peptide treatment, 
then higher B peptide toxicity was observed in the 
presence of BSA. For instance, a 35% cell growth 
decrease was observed by adding 100 nM Bl-40 peptide to 
the culture without BSA, while in the presence of 50 
Mg/ml BSA, 100 nM Bl-40 peptide inhibits cell growth by 
42%. This suggests a possible interaction between BSA 
and Bl-40 peptide.
Two further experiments were conducted at various 
Bl-40 concentrations with: 1) no BSA and 2) a BSA
concentration of 100 ^g/ml. In both experiments, cell 
growth decreased with increasing Bl-40 concentrations,
9 0
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indicating a dose-dependent toxic effect of amyloid 31—
40 peptide (Figure 5-4) . However, when data from these 
two experiments were compared, it was observed that the 
61-40 inhibition of cell growth was higher in the BSA- 
containing cultures. It appeared that 61-40 toxicity 
increased when BSA was present (Figure 5-4).
Neuroblastoma cells were also cultured at a 
constant 61-40 concentration but varying BSA 
concentrations to examine the BSA - 6 peptide
interaction. Amyloid 61-40 toxicity was calculated as 
percentage of cell growth inhibition by comparing 
cultures, which grew at the same BSA concentration, 
with or without 6 peptide treatment. As shown in Figure
5-5, with increasing BSA concentrations, amyloid 61-40 
led to a higher percentage of cell growth inhibition, 
as indicated by both cell number and cell protein 
assay. This suggests BSA could potentiate the toxicity 
of amyloid 61-40 peptide. The fact that BSA was able to 
bind to 6 peptide (Vyas et al., 1992) suggests that the 
interaction between the BSA and 61-40 peptide may be 
related to the transport of 61-40 into the cell or the 
solubility of 61-40 peptide in the media.
9 1
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5-8. Mathematical models of 61-40 toxicity Mechanism
The above experimental results indicate that 
cultured neuroblastoma cells grow more poorly in 151-40 
treated cultures. This "toxic effect" on cultured 
neuroblastoma cells could be caused by 61-40 via: 1)
inhibiting cell growth rate; 2) increasing cell death 
rate; or 3) some combination of each.
Since dLHD is an indicator of accumulated dead 
cells in the culture, the experimental data (Figure 5­
2) showed that the 61-40 treated cell culture has fewer 
dead cells than the control. The 61-40 treated culture 
also has a smaller total number of cells growing. One 
valid hypothesis based on this observation is that 61­
40 toxicity in cultured neuroblastoma cells involves 
the inhibition of cell growth rate, rather than an 
increase in the cell death rate. This growth-inhibiting 
effect would not be observed in primary neuronal 
cultures where there is little or no growth of new 
cells.
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5-8-1. . Mathematical descriptions of the
accumulated dead cells in control and in Bl-40 treated 
cultures
The neuroblastoma cell growth curve (Figure 5-1) 
indicates that the cultures were in their exponential 
growth phase from day 1 to day 5. The dLDH data 
representing accumulated dead cells in the cultures 
were obtained at day 5, falling in the range of 
exponential cell growth phase. During the exponential 
growth phase, the change of cell number can be 
expressed in the following first order differential 
equation:
dx
—  = pr 
dt
Where x is the cell number and ju is the 
instantaneous cell growth rate. Assuming the cell 
growth rate does not change with time (t) during the 
exponential cell growth phase, the cell number in the 
control group at any moment equals the solution of the 
first order differential equation
dx
—
dt
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Assuming at t=0, X(0)=X0
By integrating both sides of the equation, we get
9 6
x - V "
Where X is the total cell number in the 
culture at time t, X0 is the original cell 
number plated into the culture at t=0, ji>0 is 
cell growth rate in the control group, and 
t>0 is the time since the culture started.
Let A be the cell death rate in the control group
and A< 1. If A does not change with time during the 
exponential cell growth phase, then at any moment, 
AX0e^c cells are dying in the culture. The accumulated 
dead cells at time t (denoted by D), which corresponds
to dLDH in the control culture, is the integration of
AXoe^ from time 0 to time t. That is
D-/0W »
n
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Because the same number of cells (X0 cells) was 
plated into both control and 61-40 treated groups at 
the beginning of the culture, then at any moment t, the 
cell number in a 61-40 treated group, denoted by X^, is 
the solution of the differential equation
x
Where v is cell growth rate in 61-40 treated 
culture. Integrate both sides of the equation, we get
dx
dt
-\x
i.e.
In =vr
Where is the cell number at time t,
X0 is the cell number at t=0, v>0 is the
cell growth rate in the 61-40 peptide
treated group.
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Assume B<1 is the cell death rate in a 131-40 
treated culture, and assume B does not change with time 
during the exponential cell growth phase. Thus, at any 
moment t, there would be BX0evt cells dying. And the 
number of accumulated dead cells in 131-40 treated 
cultures (denoted as Dfi) is the integration of BX0evt 
from time 0 to time t.
BX
D»=— -(evf-1) B z  1
v
Experimentally determined D and Dn values are 
derived from dLDH data in the control group and the 61­
40 treated culture, respectively. Starting with the 
same X0, as shown in Figure 5-2, the observed dLDH in 
the control group (D) is higher than that in the 61-40 
treated group (Dn). Therefore, the function of D-Dfl is 
greater than zero, as determined experimentally. 
Theoretically, at the starting points of the cultures, 
no cells were dead. That is, when t=0, D=Dfl=0. The 
experimentally determined D atO day 1 is very close to 
zero (Figure 5-1).
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5-8-2. Possible mechanisms of 61-40 toxicity
The toxic effect of 61-40 on cultured 
neuroblastoma cells could be caused: 1) by increasing
cell death; 2) by inhibiting cell growth; or 3) by a 
combination these two mechanisms. The above three 
possibilities are discussed below.
A. First hypothesis: 61-40 increases cell death rate 
but does not inhibit cell growth
Under this hypothesis, cells grow at the same 
rate in the control and the 61-40 treated cultures, 
while the cell death rate is higher in the 61-40 
treated group than in the control group. That is, 
M=v, and B>A. Now to examine whether the function D- 
follows the experimental observation, i.e. if D- 
Db>0 .
B - z y v V ' -  1 ) - x A r - 1 )  A< B
li v
D - D s=—
n
A<B, ..A-B< 0, ve^-lfcO when tzQ  
..D-Dp< 0
That is
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D<D^
Under the hypothesis that 61-40 peptides 
increases cell death rate but does not inhibit cell 
growth rate, dLDH in the control should be lower 
than dLDH in the 61-40 treated culture. This is 
opposite to the experimental observation of a high 
dLDH in the control culture. Therefore, this 
hypothesis is not valid.
B. Second hypothesis: 61-40 peptide inhibits cell
growth rate but does not increase cell death rate in 
the culture
Under this assumption, the cell death rate is 
the same in both control and 61-40 treated groups 
(A=B). However, the cell growth rate in 61-40 
treated culture is slower than in the control group 
(M>v). Thus:
D - D f  =X0—(e^-1) -X0—(ev'-1 ) ^ v ,  A - B
p V
\i v
\i V \l V
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When t=0,
1 1 1 1  
d - d , = X q A ( - — - — - + — ) = o
r H v p. V
The first derivative of D-DB is needed to determine 
if D-D0>0. The first derivative of D-DB equals
( 0 - 0 / ­
V \l V
(o-o^'-Vtt*— -v— )
H v
(D-Dp)/=XoA(e'it-e''t)>0 when |i>v, r>0
The first derivative of D-Dfi is greater than 
zero, indicating that the value of D-DB will rise 
with increasing time. At t=0, D-Db=0. Therefore, at 
any time when t>0, D-DB is positive, the observation 
follows that dLDH in the control (D) is larger than 
the dLDH in the 61-40 treated culture (Dfl) . The 
hypothesis that 61-40 inhibits cell growth rate but 
does not increase cell death rate in the culture is 
supported by the experimental observation.
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C. Third hypothesis: 61-40 inhibits cell growth rate 
as well as increases cell death rate in the culture
In this case, not only do the cells grow more 
slowly, but also the cell death rate is higher in 
the 61-40 peptide treated culture. That is, p>v and 
A<B. Follow an analysis similar to the previous one, 
we find
D - i y V V ' -  1)-Xo-(«M-1) 
p v
D -D- =X0(—  -—  +- --) 
p v v p
Whent=0, Z)-D.=X0(---+---)= 0
p v v p
Because A, B, /i, v are constants, when t is 
sufficiently big
* p v
The first derivative of D-Dfi is needed to determine 
if D-Dfl is bigger or smaller than zero. It equals
-t\ v B .
n v
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( D - D ^ ^ X ^ ' - B e n
Because X0 is a positive real 
factor Ae;Jt-Bevt determines if (D-Dfi) 
or negative.
(D -D p^O  i f  A e^> B evt
Take the In of both sides, we get
ln(Aetl‘)>ln(2tevt)
Irii4 + | ir> ln fi + v r
That is
(| i-v)r> ln5-ln/i ^>v b>a
And therefore,
(D-D 0y > 0 i f  t>—
H ~ v
We could also prove that
(D-DpJ^O i f  r<—^ ~ ln^
ji-v
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number, the 
1 is positive
1 0 4
Combine above discussion,
D-Db=0 when t=0
D-Dfi>0 when t is sufficiently big
Infl-lru(D-DB) 1 <0 when if t<
(D-Dn) '>0 when if f>
ji-v
This means the value of D-DB starts at zero and 
decreases until time t=(InB-lnA)/ (m -v ). During this 
period, D-DB is negative (Figure 5-6) . From the time 
t= (InB-lnA) / (ju-v) . D-D^ starts to increase, eventually 
the value of D-DB becomes positive. Its biological 
meaning is that at the beginning of cell culture (t=0), 
dLDH in both control and 61-40 treated groups is zero, 
and D-Db=0. Then, during a period in which D-Dfi is 
negative, the dLDH in the control group (D) should be 
smaller than that in the 61-40 treated culture (D$). As 
time goes on, dLDH in the control eventually will be 
higher than that in the 6 peptide treated group.
The dLDH assay, conducted at day 5, indicates that 
the dLDH in the control was higher than that in the 61­
40 treated culture. Both the 2nd and 3rd hypotheses are
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consistent with the observed dLDH data. It could be 
concluded that 131-40's toxic effect on cultured 
neuroblastoma cells must involve the inhibition of cell 
growth rate. However, it may or may not involve any 
increase in cell death rate in the culture. This is 
important when considering ft peptide's toxic effects on 
continuously- growing cells. The inhibition of cell 
growth by ft peptide will not be observed in primary 
cell cultures, since these cells do not divide.
5-9. The interaction of ftl-40 with mouse neuroblastoma 
cells: a binding assay
In the previous sections, it has been demonstrated 
that the ft amyloid peptide affected growth of the 
cultured mouse neuroblastoma cells, suggesting a 
possible interaction of ftl-40 with cells. As of 1988, 
only one study using an immunohistochemical method has 
demonstrated the binding of ft amyloid to tissue (Allsop 
et al. , 1988). A peptide, 138-17, was shown to bind to
the vesicular elements of the pancreas and the adrenal 
gland. Allsop et. al. (1991) extended this study by 
showing specific binding of the 138-17 peptides to rat 
cortical gray matter membranes. In their experiments, 
binding showed a clear dependence on time, temperature,
1 0 6
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
pH, and membrane concentration. In this section, the 
possibility of the 6 amyloid peptide exerting its 
biological effects on neuroblastoma cells through a 
ligand - cell binding mechanism will be discussed.
5-9-1. Radioactive labeling of 61-40 peptide
The chemical component of 125I Bolton-Hunter 
Reagent (125I-BHR) from New England Nuclear (NEN, Du 
Pont Co., Wilmington, DE, USA) is N-succinimidyl-3-(4- 
hydroxy-3-[ 1‘i5I ] iodophenyl) propionate. The reagent's 
active ester acylates primary amine groups as well as 
reacts with water. Thus, the amine groups of two lysine 
residues in Bl-40 peptide were radioactively labeled by 
reacting with 12=II-BHR (initial specific activity of
2200 Ci/mmole) . In a NENSURE™ vial, 250 juCi of reagent 
was provided in anhydrous benzene. Immediately prior to 
using 125I-BHR for peptide labeling, the benzene was
evaporated to dryness by inserting a needle through the 
septum as an intake for a gentle stream of dry air.
About 1 mg of 61-40 peptide was dissolved in 50 ii 1 
0.1 M borate (pH 8.5) - acetonitrile buffer (65:35
v/v) . After the 125I-BHR was air dried, 6 peptide was 
added to the vial. The reaction was carried out at 4°C 
overnight. At the end of the reaction, glycine was
107
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added to reach the final concentration of 0.2 M. The 
amine group on the free glycine reacts with the excess 
unchanged ester on 125I-BHR.
Gel filtration chromatography was used to separate 
labeled 6 peptide from the glycine conjugate and 
hydrolysis products. A Sephadex G-25 column was 
eguilibrated in 1% acetic acid before adding the 
reaction mixture to the top of the column. The column 
was then washed with 1% acetic acid. Forty fractions of 
50 drops per tube were collected. Peptide components 
were monitored at a UV absorption of 252 nm. The 
radioactivity of each fraction was measured as counts 
per minute (cpm) on a Searle Automatic Gamma System, 
Model 1195. Figure 5-7 shows the separation of 125i- 
labeled 61-40 peptide from the glycine conjugate and 
hydrolysis products on a Sephadex G-25 column. The 
major UV peak was overlapped by a radioactivity peak 
which contained the radioactively labeled 61-40 
peptide. Fractions 4 - 12 in this peak were combined 
and used in the experiments.
108
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radioacLively labeled /S1 —40.
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5-9-2. No specific neuroblastoma - ft peptide binding 
was observed in three hours incubations
About 106 cells were washed and plated with FCS- 
free cell culture medium in 25 cm2 tissue flasks. After 
3 days, neuroblastoma cells were then removed from the 
tissue culture flasks, resuspended in FCS-free medium 
in test tubes, and incubated with radioactively labeled 
61-40 peptide at room temperature for 5, 15, 30, or 60 
minutes. Cells were collected by centrifugation and
washed three times with fresh medium and the
radioactivity measured on a Searle Automatic Gamma 
System. This provides a measure of the total binding of 
61-40 to neuroblastoma cells.
It was hypothesized that the non-labeled 61-40 
would compete with 125I labeled peptides for the
binding sites on cell surface and therefore block the 
specific interaction between cells and the 125I-61-40.
The addition of non-labeled 61-40 would therefore 
reduce the binding measured by radioactivity. Thus the 
nonspecific binding of 61-40 to neuroblastoma cells was 
determined with the addition of 5 times excess of non­
labeled 61-40 to the culture. The difference between 
the total and non-specific binding indicates the
specific interaction of 61-40 to neuroblastoma cells.
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However, with incubation times of up to 60 minutes at 
room temperature, no specific binding of radioactively 
labeled 61-40 to neuroblastoma cells was observed.
Since the shock of removing cells from the flasks 
may interrupt the cells' physiological condition and 
cause failure to detect neuroblastoma - 6 peptide
binding, in the next experiment, cells were first 
cultured at 37°C for two days in FCS free medium 
containing 100 Mg/ml BSA. Under a light microscope,
cells were seen to grow into a smooth monolayer.
Without physically interrupting cells, 125I 61-40 was 
added and cells were allowed to continue to grow at
37°C for up to 3 hours. Samples were collected at 
incubation times of 0.5, 1.0, and 3 hours respectively 
and were washed three times with fresh cell culture 
medium before measuring the radioactivity. Again, 
specific binding of 61-40 to neuroblastoma was not 
detected. These experimental results suggested that 61­
40 binding to neuroblastoma cells, if any, is weak and 
needs a relatively long incubation time or high
concentrations of 6 amyloid peptide.
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5-9-3. Neuroblastoma - B peptide binding was observed 
starting at the second day of incubation
Cells were cultured in FCS-free HL-1 medium with 
100 /ug/ml BSA at 37°C. At replating, radioactively 
labeled Bl-40 was added to the cell culture at a 
concentration of 500 nM. Nonspecific binding was 
assayed in the presence of 7 fold excess of non­
radioactive 61-40 to block the specific interaction 
between neuroblastoma cells and 61-40 peptides. Samples 
were taken each day from day one to day five. Cells 
were washed three times with fresh medium before 
determining the bound radioactivity. Specific binding 
was observed starting from day two (Figure 5-8) . 
Binding increased along with cell growth at least up to 
day five in the cell culture. The 6 peptide binding on 
cell surfaces was not dissociated by washing cells with 
1% acetic acid in 0.5 M NaCl, suggesting the 
possibility of internalization of 61-40 peptide into 
neuroblastoma cells.
5-9-4. Internalization of 61-40 by neuroblastoma cells
Since it is not unusual for surface-bound peptide 
to be internalized by cells, a mild acid containing
112
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Incubat ion  Time (Day)
f i g u r e  5 - 8 .  T i me  c o u r s e  of  t h e  n e u r o b l a s t o m a -  
fi p e p t i d e  i n t e r a c t i o n .  R a d i o a c t i v e l y  l a b e l e d  ( 3 1 - 4 0  
was  a d d e d  to  t h e  cel l  c u l t u r e  a t  d a y  z e r o .  On l y  
s p e c i f i c  b i n d i n g  is s h o w n  in t h i s  f i g u r e .
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
various NaCl concentrations was used to dissociate 
surface-bound peptide. Cells were either washed with 
fresh cell culture medium three times, or washed twice 
with medium and then washed a third time with 0.15 M to
1.0 M NaCl in 1% acetic acid (pH 4). The dissociation 
of surface-bound peptide by the acid and NaCl reduced 
the total as well as the non-specific binding. Specific 
binding was still observed after the dissociation of 
cell surface binding. Washing cells with higher 
concentrations of salt reduced more of the 61-40 bound 
to the cell surface. Figure 5-9 shows that about 38.9% 
specific binding was retained by cells after a 0.15M 
NaCl/HAc wash, 36.1% and 34.7% specific binding 
survived 0.5 M and 1.0 M NaCl/HAc dissociation, 
respectively, indicating about one-third of the 61-40 
is internalized into the neuroblastoma cells.
5-9-5. Neuroblastoma - 6 peptide interaction at peptide 
concentrations from 100 nM to 600 nM
Saturation studies were performed at 37°C by 
incubating cells with 125I labeled 61-40 for 2 days 
from a concentration of 50 nM up to 600 nM. Figure 5-10 
shows the neuroblastoma - 61-40 interaction at 61-40
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. _. Cells washed with med ium
. . .. Cells washed with 0.1 5M NaCl
;____ ; Cells washed with 0.5M NaCl
Cells washed with 1 .0M NaCl
f i g u r e  5 - 9 .  '['he s p e c i f i c  b i n d i n g  of /S I— 4 0  w i t h  n e u r o ­
b l a s t o m a  cel l s  u n d e r  v a r i o u s  c o n d i t i o n s .  Cel l s  w e r e  w a ­
s h e d  wi t h  1 “ a c e t i c  a c i d  c o n t a i n i n g  0 . 15  M, 0.5 M, a n d
1.0 M NaCl. r e s p e c t i v e l y ,  to  d i s s o c i a t e  b i n d i n g  on  cel l  
s u r f a c e .  The s p e c i f i c  b i n d i n g  of  ce l l s  w a s h e d  w i t h  cel l  
c u l t u r e  m e d i u m  was  t a k e n  a s  100% a n d  c o m p a r e d  w i t h  
t h a t  of  cel l s  w a s h e d  wi t h  NaCl /HAc.
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F r e e  ( 3 1 - 4 0  C o n e .  ( n M  )
Figure 5-10. Neuroblastoma - (3 peptide binding
at various /U-40 concentrations. About 0.02% of
:25
added !-/? 1-10 was bound to neuroblastoma cells
5
There were 10 cells in each counting.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
concentrations from 100 nM to 600 nM. Even though the 
binding was very weak, it was consistent in the five 
experiments. However, saturation was not reached in the 
neuroblastoma - 61-40 binding assay. A possible
explanation is that this is a complex interaction 
between the neuroblastoma cells and 61-40 peptide, 
resulting from 61-40 interacting with more than one 
type of protein, or one protein molecule interacting 
with more than one 61-40 molecule. Also, since there is 
evidence that 61-40 is internalized into the cells, 
cytoplasmic 61-40 binding molecules could be present.
5-9-6. BSA enhances neuroblastoma - 6 peptide
interaction
It was shown in section 5-7 that bovine serum 
albumin (BSA) can stimulate neuroblastoma cell growth 
and also potentiate 61-40 peptide toxicity on cultured 
neuroblastoma cells. In this binding assay, 
neuroblastoma cells were cultured in FCS-free medium at 
BSA concentrations equal zero or 100 jiig/ml. 
Radioactively labeled 61-40 was added to the culture at 
a concentration of 500 nM for 2 days. Nonspecific 
binding was measured in the presence of 3,500 nM of 
non-labeled 61-40. Figure 5-11 shows that the specific
117
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binding of 131-40 to neuroblastoma was significantly 
higher at 100 jug/ml BSA than in BSA-free medium. This 
suggests that when BSA is present, the interaction 
between neuroblastoma cells and Bl-40 peptide is 
strengthened, which is consistent with the observation 
that BSA could potentiate amyloid 31-40 peptide's 
neurotoxicity on cultured neuroblastoma cells.
5-10. Discussion
Since it has been proposed that amyloid precursor 
protein is processed to release a peptide ligand, such 
as a neuroendocrine hormone or growth factor, the 
biological activity of amyloid 3 peptide has been 
widely investigated. Using the neuro-2A cell line, 
Breen et al., (1991) suggested that 3 amyloid precursor
protein may mediate cell surface adhesion and neurite 
outgrowth. More recently, Ghiso et a l ., (1992) reported
that a C-terminal fragment of the 3 amyloid precursor 
protein, which contains the 3 amyloid peptide sequence, 
also promotes cell adhesion. They also demonstrated 
that the amino acid sequence RHDS (arginine-histidine- 
aspartate-serine; residues 5-8 of 3 amyloid peptide) 
was responsible for the adhesion - promoting activity. 
The neurotoxicity of 3 amyloid peptide was also
1 1 9
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reported in many in vitro studies on primary neuronal 
cultures (Loo et al., 1993; Forloni et a l . , 1993; Pike 
et al. , 1992; Busciglio et al. , 1993). Fraser et al. ,
(1992) have investigated several analogues of B amyloid 
peptide with respect to aggregation and fibril 
structure. They suggested that the aggregation state of 
the 3 amyloid peptide, not just its 3-conformation, may 
be correlated with toxicity.
Using continuous cell lines, this study showed 
that 3 amyloid peptide toxicity is a complex process 
involving the inhibition of cell growth. The 
experimental data indicate that neuroblastoma cell 
growth is better when BSA is present in the media.
However the 3 amyloid peptide toxicity, i.e. the
inhibition of cell growth, also increased in the 
presence of BSA. This potentiation of the 3 amyloid
peptide toxicity on continuously growing cells may be 
explained by the interaction of 3 amyloid peptides with 
other molecules. Amyloid 3 peptides have been reported 
to bind complement Clq protein (Rogers et al. , 1992),
ACT (Abraham et al., 1988), lipoprotein E (Strittmatter 
et al., 1993) and albumin (Vyas et al., 1992). Amyloid
peptide does not bind to the NK1 substance P receptor 
(Joslin et al. , 1991), but does bind to complement
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proteins and membrane receptors (Arispe et al., 1993;
Rogers et al. , 1992). Joslin et al. (1991) showed that
6 amyloid peptide binds to cultured liver cells as well 
as PC12 cells through the serpin protease inhibitor- 
enzyme complex receptor (SEC). Since the SEC receptor 
is involved in endocytosis, this may explain our 
observation that exogenous R amyloid peptide is taken 
up by neuroblastoma cells. Cotman et al. , (1992) have
suggested a threshold mechanism where, as neurons 
accumulate amyloid over time, they have a decreased 
ability to successfully overcome challenges.
The specific binding of the amyloid 131-40 peptide 
to neuroblastoma cells was identified and the peptide 
was shown to be internalized into the cells. Amyloid 
may exert its biological activity by a complex 
mechanism including specific surface binding followed 
by internalization of the /31-40 into the cell. In 
situations where a peptide ligand binds at a cell 
surface and the cell is able to internalize the 
peptide, the binding properties of the cell for that 
ligand are no longer simple. This internalization of 
the peptide opens the possibility that its effect on 
the neuropathogenesis of the disease is not limited to
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cell surface-receptor mechanisms. The observation by 
Allsop et al. (1988) that 67-18 staining was confined 
to cytoplasmic vesicles is also consistent with 
possible internalization. Many peptides act as 
autocrines, and it has been shown that receptors are 
found in vesicular elements of cells (Ottaway et al. , 
1990; Posner et al., 1985; Sussman et al., 1983). These 
results support the idea that an amyloid fragment of 
the precursor protein can function as a ligand and 
interact with normal cellular metabolism. Kowall et al.
(1991) showed that 6 amyloid induced the expression of 
Alz-50 immunoreactive proteins in neurons. Also, 
exposure of hippocampal neurons to very low 
concentrations of 6 amyloid peptide resulted in an 
induction of NGF receptors (Yankner et al., 1990a). The 
ability to induce protein synthesis and the 
internalization of the peptide ligand might indicate a 
soluble intracellular receptor protein, similar to the 
steroid hormone receptors. Translocating proteins or 
factors may also be necessary for the complex to pass 
from the cytoplasm into the nucleus.
122
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1 2 3
Ultrastructural Study of BAP - Neuroblastoma 
Interaction
Amyloid B protein is a major proteinaceous 
component in senile plaque deposited in the Alzheimer's 
disease brain. The studies described in previous 
chapters investigated the neurotoxicity of BAP to 
cultured neuroblastoma cells and discussed possible 
mechanisms of the interaction among neuroblastoma cells 
and Bl-40 peptide. However, the cellular location 
involved in the neuroblastoma - B peptide interaction 
is still unknown. Using the techniques of transmission 
electron microscopy and immunocytochemistry, this 
chapter describes the study of the neuroblastoma - B 
peptide interaction at the ultrastructural level.
6-1. Introduction
Currently the metabolism of BAPP is of intense 
interest. Since the discovery that mutations in BAPP 
can cause Alzheimer's disease, it is increasingly 
apparent that the formation and deposition of the B 
amyloid protein plays a major role in the pathogenesis 
of Alzheimer's disease.
Chapter 6
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The previously reported pathway of cellular 
maturation of BAPP results in the secretion of the 
extracellular domain of the transmembrane precursor 
protein into cerebrospinal fluid and into the medium of 
cultured cells (Palmert et al. , 1989, Weidemann et al., 
1989, Oltersdorf et al. , 1990). This BAPP metabolism
pathway is mediated by a proteolytic processing step 
which cleaves inside the BAP region and thus the 
amyloidogenesis is precluded (Sisodia et al. , 1990;
Esch et al., 1990 ). However, the secretory route might 
only represent a minor metabolic pathway. An early 
study on BAPP metabolism in Hela cells reported that 
only 30% of the initially labeled BAPP was recovered in 
the conditioned medium, suggesting that the rest of 
BAPP is rapidly degraded in the cells (Weidemann et 
al. , 1989). Meanwhile, BAPP immunoreactivity was
located in the Golgi / endoplasmic reticulum system 
(Caporaso et al. , 1994), endosomal vesicles (Dyrks et
al., 1993), and in secondary lysosomes in certain
pyramidal cell bodies of the neocortex and hippocampus 
(Benowitz et al. , 1989). It has also been shown that
full-length and degradative fragments of BAPP are 
present in a lysosome-enriched subcellular fraction 
(Haass et al., 1992). Therefore, a second BAPP
1 2 4
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processing pathway through the endosome / lysosome 
system has been suggested (Caporaso et al., 1992 ; 
Benowitz et al. , 1989; Cole et al., 1989; Haass et al., 
1992) .
The lysosomotropic drug, chloroquine, has been 
used in the study of the BAPP lysosome pathway. 
Chloroquine is a weak base that is taken up by cells 
where it is concentrated in and neutralized by the 
acidic organelle, the lysosome. The elevated pH of this 
organelle results in the inhibition of its acid- 
dependent hydrolyase activity. In cultured rat 
neuroendocrine PC12 cells, it was reported that only a 
small fraction of BAPP molecules was targeted for 
secretion, whereas the majority of BAPP molecules were 
degraded in a chloroquine-sensitive compartment. It was 
also reported that chloroquine exerted inhibitory 
effects on the degradation of mature full-length BAPP 
molecules as well as the carboxyl-terminal fragments of 
BAPP, suggesting a BAPP processing pathway involving 
acidic organelles such as endosomes or lysosomes. The 
amyloid protein precursor was rapidly proteolyzed in 
lysosomes, since BAPP could be seen in these structures 
only when lysosomal proteolysis was inhibited by 
chloroquine (Caporaso et al., 1992).
1 2 5
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Using a serine and thiol protease inhibitor 
leupeptin, which interrupts lysosomal protein 
degradation, one in vivo study of neuronal processing 
of BAPP showed the accumulation of the neuronal 
lysosomes in treated rat brains. These lysosomes, which 
contained BAPP fragments of apparent molecular weight 
8.9-15 Kd, could be labeled by antisera to the 
cytoplasmic, transmembrane, and extracellular domains 
of B amyloid precursor protein (Hajimohammadreza et 
al., 1994). This in vivo model confirmed that neurons
can process BAPP via a lysosomal pathway and that 
neuronal lysosomes in vivo contain both N-terminal and 
potentially amyloidogenic C-terminal fragments of BAPP.
Cell culture models used to explore the 
intracellular processing of BAPP in vitro have also 
identified a lysosomal/endosomal pathway which produces 
a complex set of BAPP C-terminal fragments containing 
the complete B amyloid sequence, indicating the 
endosomal / lysosomal system might be the site for 
generation of BAPP fragments that preserve intact BAP 
region and thus contribute to the pathology of 
Alzheimer's disease (Golde et al., 1992). In another in 
vitro study, Knops et al. (1992) analyzed the metabolic 
pathway of maturation of APP751 in a stably transfected
1 26
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293 cells. In the presence of the lysosomal cysteine 
protease inhibitors, they found that the co-treatment 
of the inhibitor-treated cells with chloroquine 
completely blocked the generation of BAPP fragments but 
did not significantly affect BAPP maturation or 
secretion. This result indicated the non-secretory 
pathway of BAPP degradation was mediated by a cysteine 
protease in an intracellular acidic compartment.
Nordsted et al. (1993) recently reported the
identification of BAPP in clathrin-coated vesicles 
(CCVs), which are responsible for the trafficking of 
many proteins to the endosomal compartment, including 
the transport of plasma membrane receptors and of 
proteins destined for lysosomes (Brodsky 1988).
Specific sequence of Asparagine-Proline-X-Tyrosine
(NPXY, where X represents any amino acid) have been 
identified as the signal of targeting cell-surface 
proteins to the CCVs that bud off the plasma membrane 
(Chen et al., 1990). Since the cytoplasmic domain of 
BAPP contains a NPXY (amino acid 759-762 of BAPP770) 
motif known to mediate clathrin coated pit
internalization, it is possible that BAPP could be 
reinternalized from the cell surface like a variety of 
receptors. Haass et al. (1992) and Koo et al . (1994)
1 2 7
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showed the reinternalization of BAPP by labeling cell- 
surface protein with biotin or radioactively labeled 
antibody.
The above studies provide a picture of the BAPP 
metabolism pathway: full length BAPP molecules reach
the cell surface after maturation, where they can 
either be cleaved to release soluble BAPP fragments 
into the medium or reinternalized to lysosomes, 
providing a substrate containing the intact BAP region 
to lysosomal proteases. However, these studies all 
focused on the B amyloid precursor protein. Few 
ultrastructural studies have been performed to 
understand the metabolic pathway and the 
internalization of the B amyloid protein. Since the 
interaction of B peptide with cultured neuroblastoma 
cells and the possible internalization of synthetic Bl- 
40 peptide have been demonstrated in Chapter 5, we look 
forward to studying the cellular locations which are 
responsible for the B peptide metabolism and the B 
peptide internalization at the ultrastructural level.
6-2. Ultrastructural study
In the ultrastructural study, control 
neuroblastoma cells were cultured in FCS-free HL-1
1 2 8
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medium, while 6 peptide treated cells were cultured in 
the same medium with the addition of 2 /iM 61-40 
peptide. Cells were fixed in Karnovsky's solution 
containing 1% paraformaldehyde, 1.25% glutaraldehyde in
0.1 M cacodylate buffer (pH 7.2) and 2% Os04. Cells
were embedded in Epon 812 resin and stained with 7% 
uranyl acetate and 0.1% lead citrate (See appendix V).
In the immunocytochemistry study, cells were fixed with 
a lower glutaraldehyde concentration (1%) and embedded 
in LR White. The ultrathin sections on formvar coated 
nickle grids were then processed through an 
immunocytochemistry staining procedure (See Appendix 
VI) .
The ultrastructural of control neuroblastoma cells 
is shown in Figure 6-1 and Figure 6-2. They show a 
large nucleus surrounded by a double nuclear membrane; 
and a cytoplasm rich in cellular organelles, such as 
mitochondria, Golgi apparatus, lysosomes, and other 
small cellular vesicles. Small dark stained particles 
are seen in Golgi associated vesicles. Figure 6-3 
details the structure of mitochondria, lysosome (Figure
6-3A), Golgi apparatus, and centriole (Figure 6-3B) in 
control cells.
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Figure 6-1. A neuroblastoma cell cultured in FCS- 
free medium demonstrating normal cellular structure. 
N, nucleus; M, mitochondria; G, Golgi apparatus; L, 
lysosome. Original magnification, x 7,000.
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Figure 6-2. A control cell demonstrating cellular 
organelles. The cytoplasm is rich in Golgi system 
(G) . N, nucleus; L, lysosome. Original 
magnification, x 12,000.
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Figure 6-3. A control cell. A: Demonstrating
structure of mitochondria (M) and lysosome (L). 
Original magnification x 30,000. B: Demonstrating
structure of Golgi apparatus (G) and centriole (C) . 
Original magnification, x 20,000.
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Neuroblastoma cells treated with 2 /iM 61-40 
peptide have similar cellular structure and organelles. 
Figure 6-4 and Figure 6-5 show the ultrastructural of 
61-40 treated cells with nucleus, mitochondria, 
endoplasmic reticulum, and Golgi system. The electron 
opaque structure shown in Figure 6-5 occasionally 
appears in both control and 61-40 treated neuroblastoma 
cells. However, nuclear damage was noticed only in 61­
40 treated cells. Figure 6-6A shows the darkly stained 
electron dense particles in the nucleus followed by a 
trail of light stained space starting from the edge of 
the nucleus. These dark stained particles also appeared 
in the expanded perinuclear cisternal space (Figure 6- 
6B) , which is known to be associated with endoplasmic 
reticulum, and in a vesicle connected with nuclear 
membrane (Figure 6-7), indicating this anomalous 
staining might enter the nucleus from the cytoplasm and 
cause nuclear damage .
In the immunocytochemistry study, cells were fixed 
in a low glutaraldehyde concentration and embedded in 
LR White to increase the labeling level. Peptide 61-40 
on ultrathin sections was then stained with gold 
particles. Control cells had a low labeling signal, 
which is not surprising since 6APP was reported to be
1 3 3
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Figure 6-4. A neuroblastoma cell cultured in FCS- 
free medium containing 2 /iM 61-40 peptide. N, 
nucleus; M, mitochondria, L, lysosome, Original 
magnification, x 7,000.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
135
Figure 6-5. A (31-40 treated neuroblastoma cell. 
Light stained structure is suspected to be 
lipofuscin (Li). Original magnification, x 4,400.
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Figure 6-6. Nuclear damage in cells treated with 61­
40 peptide. A: The dark stained particles (arrow) is 
surrounded by a trail of light stained space in the 
nucleus. B: The dark stained particle also appears 
in the expanded perinuclear cisternal space (arrow). 
Original magnification of both photos, x 12,000.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1 3 7
Figure 6-7. Nuclear damage in a Bl-40 treated cell, 
showing dark stained particle (arrow) in a vesicle 
connected with nuclear membrane.
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rapidly degraded in the cell (Caporaso et al. , 1992).
The Bl-40 treated cells generally had higher labeling 
than control cells, suggesting that Bl-40 treated cells 
obtain their anti-B immunoreactivity from the cell 
culture medium. Figure 6-8 shows part of a Bl-40 
treated cell. In this picture, the cellular membrane 
system seems to be associated with the cell surface.
The gold labeling along the membrane close to cell 
surface suggests the internalization of B peptide. 
However, the cellular locations of B peptide processing 
were not determined. The immunocytochemistry technique 
will need improvement to provide more conclusive 
information about B peptide internalization and its 
cellular metabolic locations.
6-3. Discussion
The B amyloid protein is the major component in 
senile plaques in the AD brain. The recent findings 
that a familial form of AD is associated with genetic 
mutations within the amyloid precursor protein 
(Chartier-Harlin et al., 1991; Goate et al. , 1991;
Murrell et al., 1991), and that cells expressing a
mutant BAPP found in familial AD secrete significantly
138
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Figure 6-8. Immunocytochemistry of a 61-40 peptide 
treated cell, demonstrating gold particles located 
along cell-surface-related cellular membrane system 
(arrow). Original magnification, x30,000.
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higher amounts of BAP (Cai et al. , 1993 ; Citron et al., 
1992), strongly support the hypothesis that BAP 
accumulation in vivo may contribute to the progression 
of Alzheimer's disease.
The B amyloid protein neurotoxicity has been 
addressed in vivo by injecting isolated AD plaque cores 
(Frautschy et al. , 1991) or synthetic BAP (Kowall et
al. , 1991) into rat brain, and in vitro by direct
addition of BAP to primary neuronal cultures (Koh et 
al. , 1990; Pike et al. , 1993; Yankner et al. , 1990a,
1990b). In all of these experimental systems BAP was 
toxic to nerve cells.
Although there is now considerable evidence that 
BAP can be cytotoxic to neuronal cells, little is known 
of the mechanism of BAP neurotoxicity. It has been 
suggested that at least one pathway of BAP toxicity 
results in free radical damage. It should be noted that 
control experiments are very important. Under serum- 
free growth conditions the effect of growth factors 
need to be further defined. Until these experiments are 
performed, alternate hypotheses involving indirect 
mechanisms of BAP toxicity are possible. Using both 
primary central nervous system cultures and clonal cell 
lines, it is shown that antioxidants such as vitamin E
1 4 0
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(Behl et al. , 1992 ; 1994a) protect cells from BAP
toxicity. Amyloid 6 protein causes increased levels of 
H202 and lipid peroxides to accumulate in cells. The 
H202 degrading enzyme catalase protects cells from BAP 
toxicity.
The process of cell death has been divided 
experimentally into two distinct pathways, necrosis and 
apoptosis. Necrosis and apoptosis differ from each
other morphologically and biochemically. Apoptosis is 
an active process of self destruction. The main
morphological characteristics of cells undergoing 
apoptosis are nuclear condensation and marginated 
chromatin, followed by the formation of apoptotic
bodies. In the next stages the cells shrink and there 
is membrane ruffling and blebbing, cellular 
fragmentation, and cell death. The key observation is 
that throughout the whole process most intracellular 
organelles remain intact. Necrosis, the other principal 
pathway of cell death, is usually the result of a
dramatic cell injury. Unlike the multistep apoptosis 
process, necrosis represents the rapid collapse of 
internal cell homeostasis initiated by massive cell 
damage. Necrotic cell increase in size due to cell 
swelling and have immediate organelle damage. This is
1 4 1
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followed by chromatin clumping and the breakdown of the 
plasma membrane. There are inconsistent reports that 
BAP induces necrosis (Behl et al., 1994b) or apoptosis 
(Forloni et al., 1993; Loo et al., 1993). Loo et al.
(1993) observed the characteristics of apoptosis in 
neuronal primary culture, including membrane blebbing, 
compaction of nuclear chromatin, and internucleosomal 
DNA fragmentation. Behl et al. (1994b), however,
reported ultrastructural damages to Golgi apparatus, 
mitochondria, and other membrane systems within the 
cytoplasm, followed by total collapse of the cytoplasm 
and cell lysis. Both of these studies used high BAP 
concentrations, (higher than 20 /iM BAP), that caused 
immediate cellular damage and cell death. Our 
experiment used a relatively low BAP concentration. The 
BAP treated cells had intact cellular organelles after 
exposure to 2 nM Bl-40 peptide for three days, but 
showed less organelle structure. Some nuclear damage 
was noticed as dark stained particles entered the 
nucleus presumably through nuclear membrane and cause 
nuclear damage. It is important to perform more 
intensive immunocytochemistry studies including serial 
sections to get a better picture of where the peptide 
is binding. The NB41A3 have a irregular topology which
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
leave precise interpretation difficult without a serial 
view. Using immunocytochemistry techniques, further 
research effort will be directed toward the study of 
BAP toxicity and its cellular metabolic pathway.
143
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Conclusions and the potential for Further 
Development of NB41A3 Cell as a Model
Since the discovery that mutations in BAPP can 
cause Alzheimer's disease, it is increasingly apparent 
that the formation of the B amyloid protein deposits 
plays a major role in the pathogenesis of Alzheimer's 
disease. It is reported that 3 amyloid precursor 
protein is expressed in a variety of tissues. However, 
3 amyloid deposits have only been observed in the
brain. How the 3 amyloid protein is generated in the
brain and how BAP affects neuronal cells are major
focuses of current research. An easy to manipulate and 
interpret model system is needed to unravel the
complexities of Alzheimer's disease at the molecular 
level.
A neuronal cell line, mouse neuroblastoma NB41A3, 
is targeted as a possible model system in this research 
and the processing of BAPP and BAP - cell interaction 
were investigated.
Immunoreactivity to the carboxyl terminal of BAPP 
detected among the membrane fraction of neuroblastoma 
cells indicated that the BAPP was produced in these
Chapter 7
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cells as a membrane protein. The BAPP C-terminal 
immunoreactivity was also observed in the conditioned 
medium, demonstrating that the BAPP C-terminal 
fragments were generated and secreted during the 
cellular processing of the BAPP (Chapter 4). This could 
be one metabolic pathway of generating B amyloid 
protein from its precursor.
The facts that mutations in BAPP are sufficient to 
cause Alzheimer's disease (Goate et a l . , 1991; Murrell
et al. , 1991; Chartier-Harlin et al. , 1991) and that
cells expressing a mutant BAPP found in familial 
Alzheimer's disease secrete significantly higher 
amounts of BAP (Citron et al., 1992; Cai et al. , 1993) 
strongly suggest that BAP contributes to the 
pathogenesis of Alzheimer's disease. Based on the 
observations in this research that the synthetic Bl-40 
peptide negatively affects cultured neuroblastoma cells 
as judged by decreasing cell numbers, decreasing cell 
protein, and release of a cytosolic enzyme (lactic 
dehydrogenase) , it can be hypothesized that the 
secreted BAP-bearing fragments also have a toxic effect 
on these cultured cells (Chapter 5). Injecting isolated 
Alzheimer's disease amyloid plaque cores (Frautschy et 
al . , 1991) or synthetic B peptide (Kowall et al., 1991)
1 4 5
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into rat brains caused brain damages, indicating BAP 
neurotoxicity in vivo. These facts suggest that the 
deposits of B amyloid protein in the Alzheimer's 
disease is partially responsible for the destruction of 
nutrites, thereby contributing to the formation of 
neuritic plagues and to neuronal death.
The mechanism of BAP - cell interaction is still a 
controversial subject. One of the possible mechanisms 
of the BAP - cell interaction might be through BAP - 
cell surface binding. To investigate this possibility, 
a synthetic Bl-40 peptide was labeled with radioactive 
125I Bolton-Hunter Reagent. These specific binding 
between radioactive!'/ labeled Bl-40 peptide and 
neuroblastoma cells was observed. Washing cells with 
dissociation buffer did not abolish the specific 
binding, suggesting internalization of the Bl-40 
peptide into the cells. The above study (Zhao et al. , 
1991b) was among the first demonstrations of the 
binding of Alzheimer's B amyloid protein to cell 
surfaces and of the BAP internalization. Haass et al.
(1992) and Koo et al. (1994) later showed the
internalization of B amyloid precursor protein into the 
cells. Thus, reinternalization of secreted BAP-bearing 
fragments might be possible.
1 4 6
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As described above, a picture of the BAPP 
metabolic pathway has been proposed: full length BAPP
molecules reach cell surface after maturation as a 
membrane protein (Kang et al. , 1987), they are cleaved
to release BAPP fragments into the cerebrospinal fluid 
or into the medium of cultured cells (Palmert et al., 
1989; Weidemann et al., 1989; Oltersdorf et al. , 1990), 
the BAPP fragments are then reinternalized into the 
cells (Haass et al., 1992; Koo et a l ., 1994) where they 
have a toxic effect and cause cellular damage. Although 
little is known about the mechanism of BAP
intracellular neurotoxicity, it has been suggested that 
BAP toxicity is a result of free radical attack on the 
cellular membrane system. Amyloid B protein has been 
observed to cause increased levels of H202 and lipid
peroxides to accumulate in cells. Antioxidant vitamin E 
and the H202 degrading enzyme, catalase, were reported 
to protect cells from BAP toxicity (Behl et al., 1992; 
1994a). In an effort to extend these studies, BAP 
effects at the ultrastructural level were investigated 
(Chapter 6). We observed nuclear damage and some light
stained structure similar to lipofuscin in Bl-40
peptide treated cells. This observation supports the 
free radical hypothesis.
1 47
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The studies described in this dissertation 
contribute to the knowledge of the BAPP processing and 
of the BAP toxicity. These studies also demonstrate 
that NB41A3 cell provides a practical in vitro model 
for studying the mechanism of Alzheimer's disease and 
amyloid toxicity.
1 48
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1 4 9
References
Abraham C.R., Selkoe D.J., and Potter H., 1988,
Immunocytochemical identification of the serine 
protease inhibitor aj^-antichymotrypsin in the 
brain amyloid deposits of Alzheimer's disease. 
Cell 52, 487-501.
Allsop D., Wong C.W. , Ikeda S-I. , Landon M. ; Kidd M. , 
and Glenner G.G., 1988, Immunohistochemical
evidence for the derivation of a peptide ligand 
from the amyloid 6-protein precursor of Alzheimer 
disease. Proc. Natl. Acad. Sci. USA 85, 2790-2794.
Allsop D., Yamamoto T. , Kametani F. , Miyazaki N. , and 
Ishii T. , 1991, Alzheimer amyloid 6/A4 peptide
binding sites and a possible "APP-secretase" 
activity associated with rat brain cortical 
membranes. Brain Res. 551, 1-9.
Araujo D.M. and Cotman C.W., 1992, 6-amyloid stimulates 
glial cells in vitro to produce growth factors 
that accumulate in senile plaques in Alzheimer's 
Disease. Brain Res. 569, 141-145.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1 5 0
Arispe N., Rojas E. , and Pollard H.B., 1993, Alzheimer
disease amyloid 6-protein forms calcium channels 
in bilayer membranes: Blockade by tromethamine and 
aluminium. Proc. Natl. Acad. Sci. USA 90, 567-571.
Atherton E., Fox H. , Harkiss D., Logan C.J., Sheppard 
R.C., and Williams B.J., 1978, A mild procedure
for sold phase peptide synthesis: use of
fluorenylmethoxy-carbonylamino acids. J. Chem. 
Soc. Chem. Commun. 13, 537-539.
Autilio-Gambetti L., Morandi A., Tabaton M. , Schaetzle
B., Kovacs D., Perry G., Greenberg B. and Gambetti 
P., 1988, The amyloid precursor protein of
Alzheimer disease is expressed as a 130 kDa 
polypeptides in various cultured cell types. FEBS 
Lett. 241, 94-98.
Barany M. , Chang Y.C., Arus C. , Rustan T. , and Frey 
W.H., 1985, Increased glycerol-3-phosphorylcholine 
in post-mortem Alzheimer's brain. Lancet 1, 517.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Behl C. , Davis J., Cole G.M., and Schubert D., 1992, 
Vitamin E protects nerve cells from amyloid 6 
protein toxicity. Biochem. Biophys. Res. Commun. 
186, 944-950
Behl C., Davis J.B., Lesley R., and Schubert D., 1994a, 
Hydrogen peroxide mediates amyloid 6 protein 
toxicity. Cell 77, 817-827.
Behl C., Davis J. B. , Klier F.G., and Schubert D. , 
1994b, Amyloid 6 peptide induces necrosis rather 
than apoptosis. Brain Res. 645, 253-264.
Benowitz L.I., Rodriguez W., Paskevich P., Mufson E.J., 
Schenk D., and Neve R.L., 1989, The amyloid
precursor is concentrated in neuronal lysosomes in 
normal and Alzheimer's disease subjects. Exp. 
Neurol. 106, 237-250.
1 5 1
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Bladier D., Joubert R., Avellana-Adalid V. Kemeny J-L., 
Doinel C., Amouroux J. and Caron M. , 1989,
Purification and characterization of a 
galactoside-binding lectin from human brain. Arch. 
Biochem. Biophys. 269, 433-439.
Blusztajn J.K., Gonzalez-Coviella I.L., Logue M. ,
Growdon J.H., and Wurtman R.J., 1990, Levels of
phospholipid catabolic intermediates, glycero- 
phosphocholine and glycerophosphoethanolamine, are 
elevated in brains of Alzheimer's disease but not 
of Down's syndrome patients. Brain Res. 536, 240­
244 .
Breen K.C., Bruce M. , and Anderton B.H., 1991, Beta
amyloid precursor protein mediates neuronal cell­
cell and cell-surface adhesion. J. Neurosci. Res.
28, 90-100.
Brenda D.S., Hilbich C. , Multhaup G., Salbaum M. ,
Beyreuther K. , and Seeburg P.H., 1988, Alzheimer's 
disease amyloidogenic glycoprotein: expression
pattern in rat brain suggests a role in cell 
contact. EMBO J. 7, 1365-1370.
1 5 2
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1 5 3
Brodsky F.M., 1988, Living with clathrin: its role in
intracellular membrane traffic. Science 242, 1396­
1402 .
Busciglio J., Yeh J., and Yankner B.A., 1993, 6-amyloid 
neurotoxicity in human cortical culture is not 
mediated by excitotoxins. J. Neurochem. 61, 1565­
1568.
Buxbaum J.D., Gandy S.E., Cicchetti P., Ehrlich M.E., 
Czernik A.J., Fracasso P., Ramabhadran T.V. , 
Unterbeck A.J., and Greengard P., 1990, Processing 
of Alzheimer 6/A4 amyloid precursor protein: 
modulation by agents that regulate protein 
phosphorylation. Proc. Natl. Acad. Sci. USA 87, 
6003-6006.
Cai X.D., Golde T.E., and Younkin S.G., 1993, Release
of excess amyloid 6-protein from a mutant amyloid
6-protein precursor. Science 259, 514-516.
Caporaso G.L., Gandy S.E., Buxbaum J.D., and Greengard 
P., 1992, Chloroquine inhibits intracellular
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
degradation but not secretion of Alzheimer 13/A4 
amyloid precursor protein. Proc. Natl. Acad. Sci.
USA 89, 2252-2256.
Caporaso G.L., Takei K. , Gandy S.E., Matteoli M., 
Mundigl 0., Greengard P., and DeCamilli P., 1994, 
Morphologic and biochemical analysis of the 
intracellular trafficking of the Alzheimer 13/A4 
amyloid precursor protein. J . Neurosci. 14, 3122­
3138.
Caputo C.B., Sygowski L.A., Scott C.W., and Sobel
I.R.E., 1992, Role of tau in the polymerization of 
peptides from 13-amyloid precursor protein. Brain 
Res. 597, 227-232.
Castro M, Marks C.B., Nilsson B. and Anderson S., 1990, 
Does the Kunitz domain from the Alzheimer's 
amyloid 13 protein precursor inhibit a kallikrein 
responsible for post-translational processing of 
nerve growth factor precursor? FEBS Lett. 267, 
207-212.
154
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Ceri H., Kobiler D. and Barondes S. H., 1981, Heparin- 
inhibitable lectin. J. Biol. Chem. 256, 390-394.
Chang C.D. and Meienhofer J. 1978, Solid phase peptide 
synthesis using mild base cleavage of Na- 
fluorenylmethyloxycarbonyl amino acids,
exemplified by a synthesis of dihydrosomatostatin. 
Int. J. Pept. Protein Res. 11, 246-249.
Chartier-Harlin M.C., Crawford F. , Houlden H. , Warren
A., Hughes D., Fidani L. , Goate A., Rossor M. , 
Roques P., Hardy J., and Mullan M. , 1991,
Mutations at codon 717 of the 6-amyloid precursor 
protein gene cause Alzheimer's disease. Nature, 
353, 844-846.
Chen W-J, Goldstein J.L., and Brown M.S., 1990, NPXY, a 
sequence often found in cytoplasmic tails, is 
required for coated pit-mediated internalization 
of the low density lipoprotein receptor. J. Biol. 
Chem. 265, 3116-3123.
Citron M., Oltersdorf T., Haass C., McConlogue L., Hung
A.Y., Seubert P., Vigo-Pelfrey C., Lieberburg I.,
155
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
and Selkoe D.J., 1992, Mutation of the 6-amyloid
precursor protein in familial Alzheimer's disease 
increases 6-protein production. Nature, 360, 672­
764 .
Cole G.M., Huynh T.V., and Saitoh T., 1989, Evidence
for lysosomal processing of amyloid 6-protein 
precursor in cultured cells. Neurochem. Res. 14, 
933-939.
Cole. G. J. and Glaser L., 1986, Heparin-binding domain 
from N-CAM is involved in neural cell-substratum 
adhesion. J . Cell Biol. 102, 403-412.
Copani A., Koh J-Y, and Cotman C.W., 1991, 6-amyloid
increases neuronal susceptibility to injury by 
glucose deprivation. NeuroReport 2, 763-765,
Corder E.H., Saunders A.M., Strittmatter W.J., 
Schmechel D.E., Gaskell P.C., Small G.W., Roses
A.D., Haines J.L., and Pericak-Vance M.A., 1993,
Gene dose of apolipoprotein E type 4 allele and 
the risk of Alzheimer's disease in late onset 
families. Science 261, 921-923.
156
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
157
Cotman C.W., Cummings B.J., and Whitson J.S., 1991, The 
role of misdirected plasticity in plaque 
biogenesis and Alzheimer's disease pathology. In 
Growth factors and Alzheimer's disease. Hefti F., 
Brachet P., Will B. , and Christen Y. (Eds.), 
Springer-Verlag, Berlin, pp.222-232.
Cotman C.W., Pike C.J., and Copani A., 1992, 6-amyloid
neurotoxicity : a discussion of in vitro findings. 
Neurobiol. Aging 13, 587-590.
Cunningham D.D. and Gurwitz D., 1989, Proteolytic
regulation of neurite outgrowth from 
neuroblastoman cells by thrombin and protease 
nexin-1. J. Cell Biochem. 39, 55-64.
Dewji N.N., Shelton E.R., Adler M.J., Chan H. W., 
Seegmiller J.E., and Coronel C. , 1990, Processing
of Alzheimer's disease-associated 6 amyloid 
precursor pretein. J. Mol. Neurosci. 2, 19-27.
Dyrks T., Dyrks E., Monning U., Urmoneit B., Turner J., 
and Beyreuther K. , 1993, Generation of 6A4 from
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
the amyloid protein precursor and fragments 
thereof. FEBS Lett. 335, 89-93.
Dyrks T. , Weidemann A., Multhaup G. , Salbaum J.M., 
Lemaire H-G, Kang J. , Muller-Hill B., Masters
C.L., and Beyreuther K. , 1988, Identification,
transmembrane orientation and biogenesis of the 
amyloid A4 precursor of Alzheimer disease. EMBO J.
7, 949-957.
Eloumami H., Bladier D., Caruelle D., Courty J., 
Joubert R. and Caron M., 1990, Soluble heparin-
binding lectins from human brain: purification,
specificity and relationship to an heparin-binding 
growth factor. Int. J. Biochem. 22, 539-544.
Esch F.S., Keim P.S., Beattie E.C., Blacher R.W.,
Culwell A.R., Oltersdorf T., McClure D., and Ward 
P.J., 1990, Cleavage of amyloid 6 peptide during
constitutive processing of its precursor. Science 
248, 1122-1124.
Flood J.F., Morley J.E., and Roberts E., 1991, Amnestic
effects in mice of four synthetic peptides
158
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
homologous to amyloid ft protein from patients with 
Alzheimer disease. Proc Natl. Acad. Sci. USA 88, 
3363-3366.
Forloni G., Chiesa R., Smiroldo S., Verga L. , Salmona 
M. , Tagliavini F. , and Angeretti N., 1993,
Apoptosis mediated neurotoxicity induced by 
chronic application of ft amyloid fragment 25-35. 
NeuroReport, 4, 523-526.
Fraser P.E., Duffy L.K., O'Malley M.B., Nguyen J. , 
Inouye H., and Kirschner D.A., 1991, Morphology
and antibody recognition of synthetic ft-amyloid 
peptides. J. Neurosci. Res. 28, 474-485.
Fraser P.E., Nguyen J.T., Inouye H. , Surewicz W.K. , 
Selkoe D.J., Podlisny M.B., and Kirschner D.A. , 
1992, Fibril formation by primate, rodent, and 
Dutch-hemorrhagic analogues of Alzheimer amyloid 
ft-protein. Biochemistry. 31, 10716-10723.
Frautschy S.A., Baird A., and Cole G.M., 1991, Effects
of injected Alzheimer ft-amyloid cores in rat 
brain. Pore. Natl Acad. Sci. USA 88, 8362-8366.
159
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1 6 0
Fukuchi K-I, Kamino K., Deeb S.S., Smith A.C., Dang T. , 
and Martin G.M., 1992, Overexpression of amyloid
precursor protein alters its normal processing and 
is associated with neurotoxicity. Biochem. 
Biophys. Res. Commun. 182, 165-173.
Gabuzda D., Busciglio J. , and Yankner B.A., 1993 ,
Inhibition of 6-amyloid production by activation 
of protein kinase C. J . Neurochem. 61, 2326-2329.
Games D., Khan K.M., Soriano F.G., Keim P.S., Davis 
D.L., Bryant K., and Lieberburg I., 1992, Lack of
Alzheimer pathology after beta amyloid protein 
injection in rat brain. Neurobiol. Aging 13, 569­
576.
Ghiso J., Rostagno A., Gardella J.E., Liem L. , Gorevic 
P.D., and Frangione B., 1992, A 109-amino-acid C-
terminal fragment of Alzheimer's disease amyloid 
precursor protein contains a sequence, -RHDS-, 
that promotes cell adhesion. Biochem. J. 288, 
1053-1059.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Giordano T. , Pan J.B., Monteggia L.M., Holzman T.F., 
Snyder S.W., Krafft G. , Ghanbari H. , and Kowall 
N.W. , 1994, Similarities between ft amyloid
peptides 1-40 and 40-1: effects on aggregation,
toxicity in vitro, and injection in young and aged 
rats. Exp. Neurol. 125, 175-182.
Glenner G.G. and Wong C.W., 1984, Alzheimer's disease: 
initial report of the purification and 
characterization of a novel cerebrovascular 
amyloid protein. Biochem. Biophys. Res. Commun. 
120, 885-890.
Glenner G.G., Wong C.W., Quaranta V. , and Eanes E.D., 
1984, The amyloid deposit in Alzheimer's disease: 
their nature and pathogenesis. Appl. Pathol. 2, 
357-369.
Goate A., Chartier-Harlin M-C., Mullan M. , Brown J., 
Crawford F., Fidani L. , Giuffra L. , Haynes A., 
Irving N., James L., Mant R., Newton P., Rooke K.,
Roques P., Talbot C., Pericak-Vance M., Roses A.,
Williamson R., Rossor M. , Owen M. , and Hardy J.,
1991, Segregation of a missense mutation in the
1 61
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
amyloid precursor protein gene with familial 
Alzheimer's disease. Nature, 349, 704-706.
162
Golde T.E., Estus S., Younkin L.H., Selkoe D.J.,
Younkin S.G., 1992, Processing of the amyloid
protein precursor to potentially amyloidogenic 
derivatives. Science 255, 728-730.
Goldgaber D., Lerman M.I., McBride O.W., Saffiotti U. , 
and Gajdusek D.C., 1987, Characterization and
chromosomal localization of a cDNA encoding brain 
amyloid of Alzheimer's disease. Science, 235, 877­
880.
Gorevic P.D., Goni F., Pons-Estel B., Alvarez F., 
Peress N.S., and Frangione B. , 1986, Isolation and 
partial characterization of neurofibrillary 
tangles and amyloid plaque core in Alzheimer's
disease: immunohistological studies. J.
Neuropathol. Exp. Neurol. 45, 647-664.
Griffin W.S.T., Stanley L.C., Ling C., White L., 
MacLeod V., Perrot L.J., White C.L.III, and Araoz
C., 1989, Brain interleukin-1 and S-100
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
immunoreactivity are elevated in Down syndrome and 
Alzheimer disease. Proc. Natl. Acad. Sci. USA 86, 
7611-7615.
Grundke-Iqbal I., Iqbal K. , Tung Y-C, Quinlan M. , 
Wisniewski H.M., and Binder L.I., 1986, Abnormal
phosphorylation of the microtubule-associated 
protein tau in Alzheimer cytoskeletal pathology. 
Proc. Natl. Acad. Sci. USA 83, 4913-4917.
Gurwitz D. and Cunningham D.D., 1990, Neurite outgrowth 
activity of protease nexin-1 on neuroblastoma 
cells requires thrombin inhibition. J. Cell 
Physiol. 142, 155-162.
Haass C. , Koo E.H., Mellon A., Hung A.Y., and Selkoe
D. J. , 1992, Targeting of cell-surface ft-amyloid
precursor protein to lysosomes: alternative
processing into amyloid-bearing fragments. Nature 
357, 500-503.
Hajimohammadreza I., Anderson V.E.R., Cavanagh J.B., 
Seville M.P., Nolan C.C., Anderton B.H., and Leigh 
P.N., 1994, 6-amyloid precursor protein fragments
163
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
and lysosomal dense bodies are found in rat brain 
neurons after ventricular infusion of leupeptin. 
Brain Res. 640, 25-32.
Hamos J.E., DeGennaro L.J., and Drachman D.A., 1989,
Synaptic loss in Alzheimer's disease and other 
dementias. Neurology 39, 355-361.
Hardy J.A. and Higgins G.A., 1992, Alzheimer's Disease:
The amyloid cascade hypothesis. Science 256, 184­
185.
Hartmann H., Eckert A., and Muller W.E., 1994,
Apolipopotein and cholesterol affect neuronal 
calcium signalling: the possible relationship to
6-amyloid neurotoxicity. Biochem. Biophys. Res. 
Commun. 200, 1185-1192.
Hayashi M., Schlesinger D.H., Kennedy D.W., and Yamada 
K. ., 1980, Isolation and characterization of a
heparin-binding domain of cellular fibronectin. J. 
Biol. Chem. 255, 10,017-10,020.
1 64
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Hensley K. , Carney J.M., Mattson M.P., Aksenova M. , 
Harris M. , Wu J.F., Floyd R.A., and Butterfield
D.A., 1994, A model for 13-amyloid aggregation and 
neurotoxicity based on free radical generation by 
the peptide: relevance to Alzheimer disease. Proc. 
Natl. Acad. Sci. USA 91, 3270-3274 .
Hilbich C., Kisters-Woike B., Reed J., Masters C.L., 
and Beyreuther K., 1991, Aggregation and secondary 
structure of synthetic amyloid BA4 peptides of 
Alzheimer's disease. J . Mol. Biol. 218, 149-163.
Hughes R.C., 1983, Glycoproteins. Chapman and Hall,
London.
Jarrett J.T. and Lansbury Jr. P.T., 1992, Amyloid
fibril formation requires a chemically 
discriminating nucleation event: studies of an
amyloidogenic sequence from the bacterial protein 
OsmB. Biochemistry 31, 12345-12352.
Jessell T.M. , Hynes M.A., and Dodd J. , 1990,
Carbohydrates and carbohydrate-binding proteins in
165
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1 6 6
the nervous sytem. Annu. Rev. Neurosci. 13, 227­
255.
Joachim C.L., Duffy L.K., Morris J.H., and Selkoe D.J., 
1988, Protein chemical and immunocytochemical 
studies of meningovascular 6-amyloid protein in 
Alzheimer's disease and normal aging. Brain Res. 
474, 100-111.
Johnson S.A., McNeill T. , Cordell B., and Finch C.E., 
1990, Relation of neuronal APP-751/APP-695 mRNA 
ratio and neuritic plaque density in Alzheimer's 
disease. Science, 248, 854-857.
Joslin G., Krause J.E., Hershey A.D., Adams S.P., 
Fallon R.J., and Perlmutter D.H., 1991, Amyloid 6- 
peptide, substance P, and bombesin bind to the 
serpin-enzyme complex receptor. J. Biol. Chem. 
266, 21897-21902.
Kammesheidt A., Boyce F.M., Spanoyannis A.F., Cummings
B.J., Ortegon M. , Cotman C., Vaught J.L., and Neve 
R.L., 1992, Deposition of 6/A4 immunoreactivity
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
and neuronal pathology in transgenic mice 
expressing the carboxyl-terminal fragment of the 
Alzheimer amyloid precursor in the brain. Proc. 
Natl. Acad. Sci. USA 89, 10857-10861.
Kang J. , Lemaire H-G, Unterbeck A. , Salbaum J.M. , 
Masters C.L., Grzeschik K-H, Multhaup G., 
Beyreuther K., and Muller-Hill B., 1987, The
precursor of Alzheimer's disease amyloid A4 
protein resembles a cell-surface receptor. Nature 
325, 733-736.
Kawabata S., Higgins G .A ., and Gordon J.W., 1991,
Amyloid plaques, neurofibrillary tangles and 
neuronal loss in brains of transgenic mice 
overexpressing a C-terminal fragment of human 
amyloid procursor protein. Nature, 354, 476-478.
Kitaguchi N., Takahashi Y., Tokushima Y., Shiojiri S., 
and Ito H., 1988, Novel precursor of Alzheimer's
disease amyloid protein shows protease inhibitory 
activity. Nature, 331, 530-532.
1 6 7
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
168
Klagsbrun M. and Shing Y., 1985, Heparin affinity of
anionic and cationic capillary endothelial cell 
gorwth factors: analysis of hypothalamus-derived
growth factors and fibroblast growth factors. 
Proc. Natl. Acad. Sci. USA 82, 805-809.
Knops J., Lieberburg I., and Sinha S., 1992, Evidence
for a nonsecretory, acidic degradation pathway for 
amyloid precursor protein in 293 cells. J . Biol. 
Chem. 267, 16022-16024.
Koh J-Y, Yang L.L., and Cotman C.W., 1990, 3-amyloid
protein increases the vulnerability of cultured 
cortical neurons to exocitotoxic damage. Brain 
Res. 533, 315-320.
Koo E.H. and Squazzo S.L., 1994, Evidence that
production and release of amyloid 3-protein 
involves the endocytic pathway. J Biol. Chem. 269, 
17386-17389 .
Kosik K.S., 1992, Alzheimer's Disease: a cell
biological perspective. Science 256, 780-783.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
169
Kowall N.W., Beal M.F., Busciglio J. , Duffy L.K., and 
Yankner B.A., 1991, An in vivo model for the
neurodegenerative effects of 6 amyloid and 
protection by substance P. Proc Natl. Acad. Sci. 
USA 88, 7247-7251.
Kowall N.W., McKee A.C., Yankner B.A., and Beal M.F., 
1992, In Vivo neurotoxicity of Beta-amyloid [6(1- 
40)] and the 6(25-35) fragment. Neurobiol. Aging 
13, 537-542.
Kowall N.W., 1994, Beta amyloid neurotoxicity and
neuronal degeneration in Alzheimer's disease. 
Neurobiol. Aging 15, 257-258.
Loo D.T., Copani A., Pike C.J., Whittemore E.R., 
Walencewicz A.J., and Cotman C.W., 1993, Apoptosis 
is induced by 6-amyloid in cultured central 
nervous system neurons. Proc. Natl. Acad. Sci. USA 
90, 7951-7955.
Lundt B.F., Johansen N.L., Voelund A., and Markussen 
J., 1978, Removal of t-butyl and t-butoxycarbonyl
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
protecting groups with trifluroacetic acid. Int.
J. Pept. Protein Res. 12, 258-268.
1 70
Masliah E., Terry R.D., DeTeresa R.M., and Hansen L.A., 
1989, Immunohistochemical quantification of the 
synapse-related protein synaptophysin in 
Alzheimer's disease. Neurosci. Lett. 103, 234-239.
Masliah E. , Terry R.D., Alford M. , DeTeresa R. , and 
Hansen L.A., 1991, Cortical and subcortical
patterns of synaptophysin-like immunoreactivity in 
Alzheimer's disease. Am. J. Pathol. 138, 235-246.
Masters C.L., Simms G. , Weinman N.A., Multhaup G., 
McDonald B.L., and Beyreuther K. , 1985a, Amyloid
plaque core protein in Alzheimer disease and Down 
syndrome. Proc. Natl. Acad. Sci. USA 82, 4245­
4249 .
Master C.L., Multhaup G. , Simms G., Pottgiesser J., 
Martins R.N., and Beyreuther K. , 1985b, Neuronal
origin of a cerebral amyloid: neurofibrillary
tangles of Alzheimer's disease contain the same
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
protein as the amyloid of plaque cores and blood 
vessels. EMBO J . 4, 2757-2763.
Mattson M.P. and Rydel R.E., 1992a, 6-amyloid precursor 
protein and Alzheimer's disease: The peptide plot 
thickens. Neurobiol. Aging 13, 617-621.
Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg
I., and Rydel R.E., 1992b, 6-amyloid peptides
destabilize calcium homeostasis and render human 
cortical neurons vulnerable to excitotoxicity. J.
Neurosci. 12, 376-389.
May P.C. Gitter B.D., Waters D.C., Simmons L.K., Becker 
G.W., Small J.S., and Robison P.M., 1992, Beta-
amyloid peptide in vitro toxicity: Lot-to-lot
variability. Neurobiol. Aging 13, 605-607.
Merrifield R.B., 1963, Solid phase peptide synthesis I.
The synthesis of a tetrapeptide. J. Am. Chem. Soc.
85, 2149-2154.
1 7 1
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1 7 2
MilliGen/Biosearch 9050 Peptide Synthesizer Operator1s 
Manual. 1991, MilliGen/Biosearch, Division of 
Millipore, Burlington, MA, USA.
Mita S., Sadlock J. Herbert J. and Schon E.A., 1988, A
cDNA specifying the human amyloid JJ precursor 
protein (ABPP) encodes a 95-kDa polypeptide. 
Nucleic Acids Res. 16, 9351.
Mitsuhashi M. , Akitaya T. , Turk C.W., and Payan D.G. 
1991, Amyloid B-protein substituent peptides do 
not interact with the substance P receptor 
expressed in cultured cells. Mol. Brain Res. 11, 
177-180.
Murrell J., Farlow M., Ghetti B., and Benson M.D., 
1991, A mutation in the amyloid precursor protein 
associated with hereditary Alzheimer's disease. 
Science 254, 97-99.
Nishimoto I., Okamoto T. , Matsuura Y. , Takahashi S., 
Okamoto T., Murayama Y., and Ogata E., 1993,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Alzheimer amyloid protein precursor complexes with 
brain GTP-binding protein G0. Nature 362, 75-79.
1 7 3
Nitsch R.M., Blusztajn J.K., Pittas A.G., Slack B.E., 
Growdon J.H., and Wurtman R.J., 1992, Evidence for 
a membrane defect in Alzheimer disease brain. 
Proc. Natl. Acad. Sci. USA 89, 1671-1675.
Noguchi S., Murakami K., Yamada N., Payami H., Kaye J. , 
Heston L.L., Bird T.D., and Schellenberg G.D., 
1993, Apolipoprotein E genotype and Alzheimer's 
disease. Lancet. 342, 737-738.
Nordstedt C. , Caporaso G.L., Thyberg J. , Gandy S.E., 
and Greengard P., 1993, Identification of the
Alzheimer 6/A4 amyloid precursor protein in 
clathrin-coated vesicles purified from PC 12 
cells. J. Biol. Chem. 268, 608-612.
Nukina N., Kanazawa I., Mannen T., and Uchida Y., 1992, 
Accumulation of amyloid precursor protein and 6- 
protein immunoreactivities in axons injured by 
cerebral infarct. Gerontology 38, (suppl 1) , 10­
14 .
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1 7 4
Oltersdorf T., Ward P.J., Henriksson T., Beattie E.C., 
Neve R., Lieberburg I., and Fritz L.C., 1990, The
Alzheimer amyloid precursor protein.
Identification of a stable intermediate in the 
biosynthetic / degradative pathway. J . Biol. Chem. 
265, 4492-4497.
Ottaway C.A., 1990, The effect of ligand
internalization on cellular binding studies of 
peptide ligands. In Neuropeptides and 
immunopeptides: messengers in a neuroimmune axis. 
O'Dorisio M.S. and Panerai A. (Eds.), Annals of 
the New York Academy of Sciences, New York, pp.45- 
59.
Palmert M.R., Podlisny M.B., Witker D.S., Oltersdorf 
T., Younkin L.H., Selkoe D.J., and Younkin S.G., 
1989, The 8-amyloid protein precursor of Alzheimer 
disease has soluble derivatives found in human 
brain and cerebrospinal fluid. Proc Natl. Acad. 
Sci. USA 86, 6338-6342.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Pardridge W.M., Vinters H.V., Yang J., Eisenberg J. , 
Choi T.B., Tourtellotte W.W., Huebner V., and 
Shively J.E., 1987, Amyloid angiopathy of
Alzheimer's disease: amino acid composition and
partial sequenc of a 4,200-dalton peptide isolated 
from cortical microvessels. J . Neurochem. 49,
1394-1401.
Patterson D., Gardiner K., Kao F-T., Tanzi R. , Watkins 
P., and Gusella J.F., 1988, Mapping of the gene
encoding the 6-amyloid precursor protein and its 
relationship to the Down syndrome region of 
chromosome 21. Proc Natl. Acad. Sci. USA 85, 8266­
8270 .
Pericake-Vance M.A., Bebout J.L., Gaskell P.C., Yamaoka 
L.H., Hung W.Y., Alberts M.J., Walker A.P., 
Bartlett R.J., Haynes C.A., Welsh K.A., Earl N.L., 
Heyman A., Clark C.M., and Roses A.D., 1991,
Linkage studies in familial Alzheimer disease: 
evidence for chromosome 19 linkage. Am. J. Hum. 
Genet. 48, 1034-1050.
175
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Pettegrew J.W., Panchalingam K., Moossy J., Martinez 
J., Rao G., and Boiler F. , 1988a, Correlation of 
phosphorus-31 magnetic resonance spectroscopy and 
morphologic findings in Alzheimer's disease. Arch. 
Neurol. 45, 1093-1096.
Pettegrew J.W., Moossy J. , Withers G. , McKeag D. , and 
Panchalingam K. , 1988b, 31P nuclear magnetic
resonance study of the brain in Alzheimer's 
disease. J. Neuropathol. Exp. Neurol., 47, 235­
248.
Pike C.J., Walencewicz A.J., Glabe C.G., and Cotman
C.W., 1991, In vitro aging of B-amyloid protein
causes peptide aggregation and neurotoxicity. 
Brain Res. 563, 311-314.
Pike C.J., Cummings B.J., and Cotman C.W., 1992, 13-
amyloid induces neuritic dystrophy in vitro: 
similarities with Alzheimer pathology. 
NeuroReport, 3, 769-772.
Pike C.J., Burdick D. , Walencewicz A.J., Glabe C.G., 
and Cotman C.W., 1993, Neurodegeneration induced
1 7 6
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
by 6-amyloid peptides in vitro: the role of
peptide assembly state. J. Neurosci. 13, 1676­
1687.
Podlisny M.B., Stephenson D.T., Frosch M.P., Lieberburg
I., Clemens J.A., and Selkoe R.J., 1992, Synthetic 
amyloid 6-protein fails to produce specific 
neurotoxicity in monkey cerebral cortex. 
Neurobiol. Aging 13, 561-567.
Ponte P., Gonzalez-DeWhitt P., Schilling J., Miller J.,
Hsu D., Greenberg B., Davis K., Wallace W., 
Leiberburg I., Fuller F., and Cordell B. , 1988, A 
new A4 amyloid mRNA contains a domain homologous 
to serine proteinase inhibitors. Nature 331, 525­
527.
Posner B.I., Khan M.N., and Bergeron J.J.M., 1985,
Receptor-mediated uptake of peptide hormones and 
other ligands. In Polypeptide hormone receptors. 
Posner B.I. (Ed.), Marcel Dekker, Inc., New York 
pp.61-90.
177
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Quon D. , Wang Y., Catalano R. , Scardina M. , Murakami 
K., and Cordell B. , 1991, Formation of B-amyloid
protein deposits in brains of transgenic mice. 
Nature, 352, 239-241.
Rogers J. , Cooper N.R., Webster S., Schultz J. , McGeer 
P.L., Styren S.D., Civin W.H., Brachova L. , Bradt
B. , Ward P., and Lieberburg I., 1992, Complement
activation by B-amyloid in Alzheimer disease. 
Proc. Natl. Acad. Sci. USA 89, 10016-10020.
Roher A.E., Ball M.J., Bhave S.V., and Wakade A.R., 
1991, B-amyloid from Alzheimer disease brains 
inhibits sprouting and survival of sympathetic 
neurons. Biochem. Biophys. Res. Commun. 174, 572­
579 .
Saitoh T., Sundsmo M. , Roch J.M. , Kimura N. , Cole G. , 
Schubert D., Oltersdorf T., and Schenk D.B., 1989, 
Secreted form of amyloid B protein precursor is 
involved in the growth regulation of fibroblasts. 
Cell 58, 615-622.
1 7 8
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Schellenberg G.D., Bird T.D., Wijsman E.M., Moore D.K., 
Boehnke M., Bryant E.M., Lampe T.H., Nochlin D., 
Sumi S.M., 1988, Absence of linkage of chromosome
21q21 markers to familial Alzheimer's disease. 
Science, 241, 1507-1510.
Schellenberg G.D., Bird T.D., Wijsman E.M., Orr H.T., 
Anderson L. , Nemens E. , White J.A., Bonnycastle 
L. , Weber J.L., Alonso M.E., Potter H., Heston 
L.L., and Martin G.M., 1992, Genetic linkage
evidence for a familial Alzheimer's disease locus 
on chromosome 14. Science, 258, 668-671.
Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain
B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A. , 
Goldgaber D., and Roses A.D., 1993, Increased
amyloid 6-peptide deposition in cerebral cortex as 
a consequence of apolipoprotein E genotype in 
late-onset Alzheimer disease. Proc. Natl. Acad. 
Sci. USA 90, 9649-9653.
Schubert D., Schroeder R. , LaCorbiere M. , Saitoh T. , 
and Cole G., 1988, Amyloid 6 protein precursor is
1 7 9
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
possibly a heparin sulfate proteoglycan core 
protein. Science 241, 223-226.
180
Schubert D., LaCorbiere M. , Saitoh T., and Cole G. , 
1989, Characterization of an amyloid precursor 
protein that binds heparin and contains tyrosine 
sulfate. Proc. Natl. Acad. Sci. USA 86, 2066-2069.
Scott G.K., 1992, Proteinases and proteinase inhibitors 
as modulators of animal cell growth. Comp. 
Biochem. Physiol. 103B, 785-793.
Selkoe D.J., Podlisny M.B., Joachim C.L., Vickers E.A., 
Lee G. , Fritz L.C., and Oltersdorf T. , 1988, 8-
amyloid precursor protein of Alzheimer's disease 
occurs as 110 to 135-kilodalton membrane- 
associated proteins in neural and nonneural 
tissues. Proc. Natl. Acad. Sci. USA 85, 7341-7345.
Simpson J. , Bladon C.M., Yates C.M., and Harmar A. J. , 
1989, An antiserum to the extracellular domain of 
the Alzheimer amyloid precursor recognizes 70 and 
88 kDa brain proteins. FEBS Lett. 257, 238-240.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Sisodia S.S., Koo E.H., Beyreuther K. , Unterbeck A., 
and Price D.L., 1990, Evidence that B-amyloid
protein in Alzheimer's disease is not derived by 
normal processing. Science 248, 492-495.
Smith R.P., Higuchi D.A. , and Broze G.J. Jr., 1990, 
Platelet coagulation factor XIa-inhibitor, a form 
of Alzheimer amyloid precursor protein. Science 
248, 1126-1128.
Snow A.D., Willmer J. , and Kisilevsky R., 1987,
Sulfated glycosaminoglycans in Alzheimer's 
disease. Hum. Pathol. 18, 506-510.
Snow A . D . and Wight T.N. , 1989, Proteoglycans in the
pathogenesis of Alzheimer's disease and other 
amyloidoses. Neurobiol. Aging 10, 481-497.
St. George-Hyslop P.H., Tanzi R., Polinsky R.J., Haines 
J.L., Nee L. , Watkins P.C., Myers R.H., Feldman 
R.G., Pollen D., Drachman D., Growdon J. , Bruni
A., Foncin J-F., Salman D., Frommelt P., Amaducci 
L. , Sorbi S., Piacentini S., Stewart G.D., Hobbs 
W.J., Conneally P.M., and Gusella J.F., 1987, The
1 8 1
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
genetic defect causing faimilial Alzheimer's 
disease maps on chromosome 21. Science 235, 885­
890.
Strittmatter W.J., Saunders A.M., Schmechel D. , 
Pericak-Vance M. , Enghild J., Salvesen G.S., and 
Roses A.D., 1993, Apolipoprotein E: high-avidity
binding to 3-amyloid and increased frequency of 
type 4 allele in late-onset familial Alzheimer 
disease. Proc. Natl. Acad. Sci. USA 90, 1977-1981.
Sussman K.E., Pollard H.B., Leitner J.W., Nesher R. , 
Adler J., and Cerasi E., 1983, Differential
control of insulin secretion and somatostatin- 
receptor recruitment in isolated pancreatic 
islets. Biochem J. 214, 225-230.
Tam J.P., 1988, Acid deprotection reactions in peptide 
synthesis. In Macromolecular sequencing and 
synthesis: Selecccted methods and applications.
David H. (Ed.), Schlesinger, Alan R. Liss, Inc.,
New York. pp.153-184.
1 8 2
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Tanaka S., Nakamura S., Ueda K., Kameyama M . , Shiojiri
S., Takahashi Y., Kitaguchi N. , and Ito H., 1988, 
Three types of amyloid protein precursor mRNA in 
human brain: their differential expression in
Alzheimer's disease. Biochem. Biophys. Res. 
Commun. 157, 472-479.
Tanzi R.E., St. George-Hyslop P.H., Haines J.L., 
Polinsky R.J., Nee L. , Foncin J-F, Neve R.L., 
McClatchey A.I., Conneally P.M., and Gusella J.F., 
1987, The genetic defect in familial Alzheimer's 
disease is not tightly linked to the amyloid B- 
protein gene. Nature, 329, 156-157.
Tanzi R.E., McClatchey A.I., Lamperti E.D., Villa- 
Komaroff L. , Gueslla J.F., and Neve R.L., 1988,
Protease inhibitor domain encoded by an amyloid 
protein precursor mRNA associated with Alzheimer's 
disease. Nature, 331, 528-530.
Terry R. and Katzman R. , 1983, Senile dementia of the
Alzheimer type: defining a disease. In The
Neurology of Aging. Katzman R. and Terry R. 
(Eds.), Philadelphia: F.A. Davis, pp. 51-84.
183
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1 8 4
Vyas S., Zhao X., Luick T.J., and Duffy L.K., 1992, 6- 
amyloid peptides, aluminum and albumin. In 
Treatment of Dementias. Meyer E.M., Simpkins J.W., 
Yamamoto J., and Crews F.T. (Eds.), Plenum Press, 
New York, pp.503-513.
Waudelen C.V., Zeikus R., and Tsou D., 1989, Cleavage, 
deprotection and isolation of peptides after Fmoc 
synthesis. Chemistry Update. MilliGen/Biosearch, 
Division of Millipore.
Weidemann A., Konig G., Bunke D., Fischer P., Salbaum 
J.M., Masters C.L., and Beyreuther K. , 1989,
Identification, biogenesis, and localization of 
precursors of Alzheimer's disease A4 amyloid 
protein. Cell 57, 115-126.
Whitson J.S., Selkoe D.J., and Cotman C.W., 1989,
Amyloid 6-protein enhances the survival of 
hippocampal neurons in vitro. Science 243, 1488­
1490.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Whitson J.S., Glabe C.G., Shintani E. , Abcar A., and 
Cotman C.W., 1990, 6-amyloid protein promotes
neuritic branching in hippocampal cultures. 
Neurosci. Lett. 110, 319-324.
Wirak D.O., Bayney R. , Ramabhadran T.V., Fracasso R.P., 
Hart J.T., Hauer P.E., Hsiau P., Pekar S.K., 
Scangos G.A., Trapp B.D., and Unterbeck A.J.,
1991, Deposits of amyloid 6 protein in the central 
nervous system of transgenic mice. Science 253, 
323-325.
Yankner B.A., Dawes L.R., Fisher S., Villa-Komaroff L., 
Oster-Granite M.L., and Neve R.L., 1989,
Neurotoxicity of a fragment of the amyloid 
precursor associated with Alzheimer's disease.
Science 245, 417-420.
Yankner B.A., Caceres A., and Duffy L.K., 1990a, Nerve
growth factor potentiates the neurotoxicity of 13- 
amyloid. Proc. Natl. Acad. Sci. USA 87, 9020-9023.
Yankner B.A., Duffy L.K., and Kirschner D.A., 1990b,
Neurotrophic and neurotoxic effects of amyloid 6-
1 8 5
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
protein: reversal by tachykinin neuropeptides.
Science 250, 279-282.
Yankner B.A. and Mesulam M.M., 1991, 6-amyloid and the 
pathogenesis of Alzheimer's disease. The New Engl.
J. Med. 325, 1849-1857.
Yankner B.A., 1992, Commentary and perspective on
studies of 6-amyloid neurotoxicity. Neurobiol. 
Aging 13, 615-616.
Zabel B.U., Salbaum J.M., Multhaup G. , Masters C.L., 
Bohl J. , and Beyreuther K. , 1987, Sublocation of
the gene for the precursor of Alzheimer's disease 
amyloid A4 protein on chromosome21. Cytogenet. 
Cell Genet. 46, 725-726.
Zhao X, Schoenheit C., and Duffy L.K., 1991a, A
heparin-binding protein from neuroblastoma cells: 
immunological comparison to 6-amyloid precursor 
protein. Comp. Biochem. Physiol. 100A, 715-718.
1 8 6
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Zhao X. and Duffy L.K., 1991b, On the interaction of a 
synthetic Alzheimer B-amyloid peptide with NB41A3 
cells. Neurosci. Res. Commun. 9 , 159-166.
Zhao X., Valantas J.A. , Vyas S., and Duffy L.K., 1993,
Comparative toxicity of amyloid B-peptide in 
neuroblastoma cell lines: effects of albumin and
physalaemin. Comp. Biochem. Physiol. 106C, 165­
170.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
188
Appendices
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1 8 9
Appendix I. Cell Culture Media
Cells in vivo exist in and react to a complex 
set of nutritional, hormonal, and stromal 
influences. If a cell is to survive or proliferate 
when removed from an animal and placed in culture, 
the medium must carry out the functions previously 
served by the complicated external in vivo 
environment of the cell. The media originally used 
for the growth of mammalian cells were based on 
biological fluid such as plasma and embryonic 
extracts. However, such chemically undefined media 
suffer from many disadvantages including batch 
variation and vulnerability to contamination.
Eagle's minimum essential medium (EMEM) is a 
chemically defined medium which contains a minimum 
number of components shown to be essential for cell 
growth. The components of the formulation include a 
complex mixture of salts, carbohydrates, amino 
acids, and vitamins. Dulbecco's modified Eagle's 
medium (DMEM) has higher concentrations of amino 
acid and vitamins than Eagle's medium as well as 
additional nonessential amino acids and added ferric
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
nitrate. Ham's F12 medium is another chemically 
defined medium with a complex composition including 
various trace elements (Table 1-1).
Most cultured cells, however, will not survive 
or exhibit optimal phenotypic properties for long 
periods of time in basal culture medium alone, and 
require serum supplementation. This reflects 
additional requirements for growth factors, 
hormones, transport proteins, and trace elements.
One of the most effective serum supplements for cell 
growth is fetal calf serum because of its high 
content of embryonic growth factors. Serum is a 
complex heterogeneous mixtures of proteins, 
hormones, growth factors, lipids, and other known 
and unknown factors, whose concentrations could vary 
greatly depending on the donor and the particular 
batch used. It could introduce variability in 
experimental results.
Therefore, the use of chemically defined serum- 
free media for cultured cells has many advantages.
The combination of F12 and DMEM (1:1) has been the 
basis of the development of some serum-free 
formulations. Factors most commonly added to
1 9 0
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Table 1-1. Chemical components of DMEM and F12*
Component (mg/1) DMEM F12
Amino acids
L-Alanine 8 . 9
L-Arginine 84.0 211.0
L-Asparagine 15 . 0
L-Aspartic acid 13 . 3
L-Cysteine 62.6 35.1
L-Glutamic acid 14 . 7
L-Glutamine** 584 .0 146. 0
Glycine 30.0 7.5
L-Histidine 42 . 0 21.0
L-Isoleucine 105.0 3 . 9
L-Leucine 105. 0 13 . 1
L-Lysine 146.0 36.5
L-Methionine 30.0 4.5
L-Phenylalanine 66.0 5.0
L-Proline 34 . 5
L-Serine 42 . 0 10. 5
L-Threonine 95. 0 11.9
L-Tryptophan 16. 0 2 . 0
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Table I-l. Continued
Component (mg/L) DMEM F12
L-Tyrosine 103 . 8 7.8
L-Valine 94 . 0 11.7
Vitamins
B-12 1.4
Biotin 0 . 007
Choline chloride 4 . 0 14 . 0
Folic acid 4 . 0 1.3
Inositol 7 . 2 18. 0
Niacinamide 0. 04
Nicotinamide 4 . 0
D-Pantothenic acid 4 . 0 0.5
Pyridoxal 4 . 0
Pyridoxine 0. 06
Riboflavin 0.4 0. 04
Thiamine 4.0 0.3
Inorganic salts
Calcium chloride 200 . 0 33 . 2
Copper sulfate 0.0025
Iron nitrate 0.1
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Table 1-1. Continued
Component (mg/L) DMEM F12
Iron sulfate 0.83
Magnesium chloride 57 . 2
Magnesium sulfate 97.7
Potassium chloride 400. 0 223 . 6
Sodium chloride 6400.0 7599.0
Sodium phosphate 125. 0 142 . 0
Zinc sulfate 0.9
Other
D-Glucose 4500.0 1802.0
Hypoxanthine 4 . 8
Linoleic acid 0.084
Lipoic acid 0.2
Putrescine 0. 16
Sodium pyruvate 110. 0
Thymidine 0.7
* Formulations are from Bottenstein 1992.
** Glutamine is added immediately prior to use.
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chemically defined media base are polypeptide hormone 
insulin, the iron-transport protein transferrin, and 
the trace element selenium. The other components vary 
depending on the cell type.
Serum-free formulations have been found suitable 
for many in vitro cell growth studies. A rat 
neuroblastoma B104 cell has been shown to successfully 
grown in DMEM/F12 (1:1) with supplement of 5 nq/ml 
insulin, 5 jug/ml transferrin, 30 nM sodium selenite, 
and 20 nM progesterone (Bottenstein et al., 1979a;
1979b). In this study for culturing mouse neuroblastoma 
NB41A3 cells, the commercially available serum-free 
medium HL-1 was used. Supplied by Ventrex (Ventrex 
Laboratories, Inc., Portland, ME, USA), HL-1 is a 
DMEM/F12 basal medium with supplement of insulin, 
transferrin, testosterone, sodium selenite, and fatty 
acids. HEPES (N-2-hydroxyethyl piperazine-N'-2- 
ethanesulfonic acid) is used as buffering system and 
phenol red is used as a pH indicator in the medium. HL-
1 medium contains less than 50 nq/ml total protein and 
does not contain albumin, serum, or growth factors such 
as EGF, FGF, PDGF, estrogen, and progesterone. Table I-
2 shows the components added in the HL-1 medium.
194
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Table 1-2. HL-1 serum-free medium*
Component Concentrations
Insulin (bovine source) 15 nq/ml
Transferrin (human source) 10 jug/ml
Testosterone
Ethanolamine
Sodium Selenite
Variety of fatty acids
HEPES 15 mM
Biocarbonate 2.2 g/L
Glucose 6 g/L
Phenol Red
* From Ventrex technical notes. All other 
additives are proprietary.
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Appendix II. Micro BCA Protein Determination
The Micro BCA protein assay is a highly sensitive 
method for protein determination. When protein is 
placed in an alkaline condition containing Cu2+, a 
color complex can form between the peptide bounds of 
the protein and the copper atoms. This is the well- 
known Biuret Reaction. When bicinchoninic acid (BCA) is 
introduced in this system, it greatly increases the 
sensitivity of the protein assay. This method is also 
compatible with commonly encountered biochemical 
reagents, such as 1% Triton X-100, SDS, and sodium 
phosphate buffer.
Il-l. Preparation of Working Reagent.
The Micro BCA Protein Assay Reagent (Pierce,
Rockford, IL) is supplied in three separate bottles: 
Micro Reagent A (MA) contains sodium carbonate, 
sodium bicarbonate, and sodium tartrate in 0.2 N 
NaOH.
Micro Reagent B (MB) contains 4% BCA in water. 
Micro Reagent C (MC) contains 4% cupric sulfate, 
pentahydrate in water.
To prepare the Micro Working Reagent, mix:
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1 9 8
2 parts of MC and 48 parts of MB.
Then, add 50 parts of MA.
This Working Reagent is stable for one day at room 
temperature.
II-2. Standard Protocol of Micro BCA Protein Assay.
A. Prepare a set of protein standards of
concentration ranging from 0 to 20 nq per
milliliter in the same diluent as in the unknown
samples.
B. Pipette 1.0 ml of each standard or unknown 
protein into the appropriately labeled test tube. 
For blanks, use 1.0 ml of diluent.
C. Add 1.0 ml Working Reagent to each tube. Mix
well.
D. Incubate all tubes at 60°C for 60 minutes.
E. Cool all tubes to room temperature. Measure the 
absorbance at 562 nm of each tube.
F. Prepare the standard curve by plotting the net 
absorbance at 562 nm vs. protein concentration. 
Using this standard curve, determine the protein 
concentration for each unknown protein sample.
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Appendix III. SDS-Polyacrylamide Electrophoresis 
III-l. Stocking Solutions
A. 30% Aerylamide/bis 
Acrylamide 87.6 g
N 1N '-bis-methylene-acrylamide 2.4 g
Make to 300 ml with distilled water. Filter and
store at 4°C in the dark (30 days maximum).
B. 1.5 M Tris-HCl, pH 8.8 
Tris base 27.23 g
Add 80 ml distilled water
Adjust to pH 8.8 with 1 N HCl. Make to 150 ml 
with distilled water and store at 4°C.
C. 0.5 M Tris-HCl, pH 6.8 
Tris base 6 g
Add 60 ml distilled water
Adjust to pH 6.8 with 1 N HCl. Make to 100 ml 
with distilled water and store at 4°C.
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Dissolve 10 g SDS with gentle stirring and 
bring to 100 ml with distilled water.
D . 10% S D S
E. SDS-PAGE Sample Buffer
Distilled water 4 .0 ml
0.5 M Tris-HCl, pH 6.8 1.0 ml
Glycerol 0.8 ml
10% (w/v) SDS 1.6 ml
2-B-mercaptoethanol 0 . 4 ml
0.05% (w/v) bromophenol blue 0.2 ml
Total 8.0 ml
Dilute the sample at least 1:4 with sample 
buffer, and heat at 95°C for 4 minutes.
F. 5x Electrode (Running) Buffer, pH 8.3 
Tris base 9.0 g
Glycine 43.2 g
SDS 3.0 g
Make to 600 ml with distilled water. Store at 
4°C.
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Dilute 60 ml 5x stock with 240 ml distilled water 
for one electrophoretic run.
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III-2. 9.0% Separating Gel Preparation, pH 8.8
Distilled water 4.85 ml
1.5 M Tris-HCl, pH 8.8 2 . 5 ml
10% SDS 100 n 1
30% Acrylamide/bis 3.0 ml
*10% Ammonium persulfate 50 yu 1
(fresh daily)
**TEMED 5 ill
Total 10 ml
*To make the 10% ammonium persulfate solution, 
dissolve 100 mg Ammonium Persulfate in one ml 
distilled water.
**TEMED: N ,N ,N ',N 1-Tetramethylethylenediamine.
Ill—3. 4.0% Stacking Gel Preparation, pH 6.8
Distilled water 6.1 ml
0.5 M Tris-HCl, pH 6.8 2.5 ml
10% (w/v) SDS 100 ill
Acrylamide/bis (30% stock) 1.3 ml
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Degas for 15 minutes at room temperature
10% ammonium persulfate 50 ill
(fresh daily)
TEMED 10 Ml
Total 10 ml
III-4. Running Conditions
The power condition for optimal resolution is 200 
volts, constant voltage setting.
III-5. Coomassie Blue Staining of the Gel
Stain the gel for half an hour with 0.1% Coomassie 
blue R-250 in 40% methanol and 10% acetic acid. 
Destain the gel with 40% methanol, 10% acetic acid 
to remove background.
The sensitivity of protein detection is in the 
microgram range.
Reference
Mini-Protean II Dual Slab Cell Instruction Manual. Bio­
Rad Laboratories, Richmond, CA, USA.
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Appendix IV. Western Blot Protocol
A. Resolve proteins on SDS-PAGE
B. Blot proteins on Immobilon transfer membrane using a 
Bio-Rad semi-dry electroblotter. Set power supply at 
230 mA. Bloting time is 2 hours.
C. Block non-specific binding sites on the membrane 
with 5% dry milk in 10 mM phosphate, 150 mM NaCl,
0.05% tween 20, pH 7.2 at 4°C overnight.
D. Wash the membrane 3x10 minutes with 10 mM phosphate, 
150 mM NaCl (PBS) containing 0.05% tween 20.
E. Incubate the membrane with primary antibody for 2 
hours at room temperature.
Dilute the antibody against the synthetic BAPP C- 
peptide 1:50 with PBS buffer containing 0.05% 
tween 20 and 3% bovine serum albumin (BSA).
F. Wash the membrane 3x10 minutes with 0.05% tween 20 
in PBS.
G. Incubate the membrane with the secondary antibody 
for 2 hours at room temperature.
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Dilute anti-rabbit IgG-peroxidase conjugates 1:500 
with PBS containing 0.05% tween 20 and 3% BSA.
H. Wash the membrane 3x10 minutes with 0.05% tween 20 
in PBS.
I. Develop a color complex.
To prepare substrate solution, mix:
2.5 mg DAB (3,3' -diaminobenzidine) and 40 jul 3% 
H202 in 10 ml PBS.
Incubate the membrane with substrate solution.
Stop the enzyme-substrate reaction by washing the 
membrane with distilled water.
Reference
Bjerrum O.J. and Heegaard N.H.H. (Eds.), 1988, CRC
handbook of immunoblotting of proteins. Volume I, 
Technical descriptions. CRC Press, Inc. Florida.
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Appendix V. Ultrastructure Study Protocol
V-l. Cell Culture
Control mouse neuroblastoma NB41A3 cells were 
cultured in fetal calf serum-free HL-1 medium (Ventrex 
Laboratories, Inc., Portland, ME, USA). Amyloid 13 
peptide treated cells were cultured in the medium 
containing 2 juM Bl-40 peptide. In three days, cells 
grew into a smooth monolayer in the cell culture flask 
under light microscope. Floating dead cells were 
removed by decanting cell culture medium. Cells were 
then washed with PBS buffer containing 10 mM phosphate 
and 150 mM NaCl (pH 7.2).
V-2. Sample Preparing Protocol
A. Fixation
Fix cells with Karnovsky's fix (1% 
paraformaldehyde, 1.25% glutaraldehyde in 0.1 
M cacodylate, 5% sucrose pH 7.2) for 2 hours 
at 4°C.
Wash cells with 0.1 M cacodylate buffer 3x15 
minutes.
Fix cells with 2% 0S04 for 1.5 hours at 4°C.
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1x15 minutes 
1x15 minutes 
2x15 minutes 
2x15 minutes 
3x15 minutes 
3x15 minutes
Propylene Oxide 
Propylene Oxide 
Propylene Oxide
B. Dehydration
30% ethanol 
50% ethanol 
70% ethanol 
95% ethanol 
100% ethanol 
Propylene Oxide
C. Infiltration
1:3 Epon 812 : Propylene 1 hour
1:1 Epon 812 : Propylene 4 hour
3:1 Epon 812 : Propylene  overnight
D. Polymerization
To 20 ml Epon 812, add 0.3 ml DMP-30 
immediately prior to use. Embed neuroblastoma 
cells in the Epon 812. Incubate at 58°C for 48 
hours. Sectioning.
E. Staining
Stain sections with 7% uranyl acetate in 50% 
methanol for 10 minutes.
Wash sections with distilled water for 1 
minute.
Stain sections with 0.1% lead citrate for 10 
minutes.
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Wash sections with distilled water for 1 
minutes.
Air dry.
Observe under transmission electron 
microscope.
References
Iron K., 1993, Technical notes: fixation protocol.
Newman G.R. and Hobot J.A., 1993, Resin microscopy and 
on-section immunocytochemistry. Springer-Verlag, 
Berlin.
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Appendix VI. Immunocytochemistry Protocol
Mouse neuroblastoma cells were cultured in fetal 
calf serum-free HL-1 medium and handled as described in 
Appendix V. To increase the immunosensitivities, cells 
were fixed in 1% glutaraldehyde only, but not in Os04. 
Cells were then partially dehydrated and embedded in LR 
White. The following describes the procedure in detail.
VI-l. Sample Preparing Protocol
A. Fixation
Fix cells with 1% glutaraldehyde in 0.1 M 
cacodylate, 5% sucrose (pH 7.2) for 1 hours at 
4°C.
Wash cells with 0.1 M cacodylate, 5% sucrose 
3x15 minutes.
B. Dehydration
30% ethanol 1x15 minutes
50% ethanol 1x15 minutes
70% ethanol 1x15 minutes
70% ethanol overnight
C. Infiltration
2:1 LR White : 70% ethanol 1 hour 
LR White 1 hour
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LR White overnight
D. Polymerization
Embed neuroblastoma cells in LR White. 
Incubate at 50°C for 24 hours. Sectioning.
VI-2. Immunogold Staining
A. Wash sections with distilled water for 1 minutes.
B. Wash sections with 5% FCS in 10 mM phosphate, 150 
mM NaCl, 0.1 M Glycine (PBS-Glycine buffer, pH
7.2) 3x1 minute.
C. Primary antibody incubation. Dilute rabbit anti- 
BAP 1:10 with 5% FCS in PBS-Glycine buffer (pH
7.2). Incubate sections with anti-BAP dilution for 
1 hour.
D. Wash sections with 5% FCS in PBS-Glycine buffer 
(pH 7.2) 3x1 minute.
E. Wash sections with 1% FCS in PBS-Glycine buffer 
(pH 8.6) 3x1 minute.
F. Secondary antibody incubation. Dilute 15 nm gold 
conjugated goat anti-rabbit IgG (E-Y Laboratories, 
Inc., San Mateo, CA, USA) 1:10 with 1% FCS PBS- 
Glycine buffer (pH 8.6). Incubate sections with 
secondary antibody for 1 hour.
G. Wash sections with PBS (pH 7.2) 3x1 minute.
2 1 0
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H. Wash sections with distilled water 3x1 minute.
Air Dry.
I. Stain sections with 7% uranyl acetate in 50% 
methanol. Wash sections with distilled water for 1 
minute.
J. Stain sections with 0.1% lead citrate. Wash 
sections with distilled water for 1 minute. Air 
dry.
K. Observe samples under transmission electron 
microscope.
References
Iron K., 1993, Technical notes: fixation protocol.
Iron K., 1993, Technical notes: immunocytochemistry
staining protocol.
Newman G.R. and Hobot J.A., 1993, Resin microscopy and
on-section immunocytochemistry. Springer-Verlag, 
Berlin.
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